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INTRODUCTION

This project is comprised of three main areas of investigation of
human cytomegalovirus (HCMV). The first of these areas is the development
of DNA probes derived from HCMV strain AD169 for the rapid detection of
HCMV in clinical samples.
a

large

Three probes were selected and tested against

number of clinical

samples.

hybridize with herpes simplex virus

One

probe was

types 1 and 2

found

(HSV-1,

to

cross-

HSV-2)

DNA

controls.
This

observation

led

to

the

investigation

of

the

cross-

hybridization, which was localized to specific restriction fragments of
HCMV and HSV-1.

Since the particular HSV-1 restriction fragment was known

to

viral

encode

the

DNA

polymerase,

it

appeared

likely

that

the

corresponding fragment of HCMV encoded the HCMV DNA polymerase.
The viral DNA polymerases of HCMV and HSV are targets for a number
of antiviral agents.

Therefore,

the third and most extensive area of

investigation was the isolation and characterization of drug-resistant
mutants of HCMV.

Three mutants of HCMV AD169 which were resistant to

ganciclovir (GCV) were isolated.

Although the viral DNA polymerase is a

target for GCV, this drug requires intracellular phosphorylation in order
to become therapeutically active.
The three mutants were characterized by high performance liquid
chromatography (HPLC) for the study of GCV anabolism in infected cells.

1

2

It was found that extracts of cells infected with each of the mutants
contained much lower levels of the phosphorylated derivatives
compared to

the

These

cells.

responsible

for

levels of the
data

suggested

same derivatives
that

a

in wild-type- infected

virus-specific

GCV phosphorylation was

of GCV

decreased

kinase

activity

in mutant-infected

cells.
Three experimental approaches were devised to characterize this new
HCMV GCV kinase function.

The first approach was in vitro translation and

expression of enzyme activity.

Preston (121)

reported that the HSV-1

thymidine kinase (TK) activity could be detected from in vitro translation
products of RNA isolated from infected cells.

Since the TK of HSV-1 is

known to phosphorylate GCV in HSV-1-infected cells,

similar

in vitro

translation experiments were performed using HCMV mRNA.
The second approach was marker transfer (33,114) of GCV resistance
from mutant to wild-type virus.
mutants.

A cosmid library was made of one of the

Marker transfer experiments were performed by transfecting human

foreskin fibroblasts (HFF) with individually selected cosmids.

The HFF

were either co-transfected with wild-type genomic DNA or subsequently
infected with wild-type virus.

The transfected cells were cultured in the

presence of GCV for selection of recombinant progeny.
The third approach was to compare infected cell proteins from mutant
and

wild-type-infected

electrophoresis.

cells

by

two-dimensional

polyacrylamide

gel

Comparison of mutant and wild- type proteins by this

method revealed a protein which was present in the wild-type HCMV AD169
but absent in uninfected and mutant-infected cells.

LITERATURE REVIEW

Structure and growth characteristics.
is a member of the family Herpesvirideae.

Human cytomegalovirus (HCMV)

These viruses generally produce

primary infections which become latent and may later reactivate.

Other

human viruses which are classified in this family include Epstein-Barr
virus (EBV), herpes simplex types 1 and 2 (HSV-1, HSV-2) and varicellazoster (VZV).

The growth characteristics of these viruses in cell culture

differ with respect to permissive cell type, length of replication cycle
and extracellular viral titer (38).

HSV types 1 and 2 grow in a variety

of mammalian cells with a short replication cycle resulting in release of
the

virions

into

the

extracellular

fluid.

By

comparison

the

only

permissive cells for HCMV replication are human diploid fibroblasts.
Replication occurs very slowly and there is little release of virus into
the cell culture fluid.

Repeated passage of HCMV isolates in culture may

eventually result in measurable viral titer in the extracellular fluid,
however, the titer varies with the particular strain of virus.

There are

a number of well-characterized laboratory strains (36,78,87,126) derived
from clinical isolates after multiple cell-culture passage.
differ

from

their

initial

extracellular viral titers.

isolates

by

producing

These strains

relatively

high

The strain used in all of the experiments for

this project was AD169 (137).
The complete virion of HCMV is composed of a double-stranded linear
3

4
DNA-containing core,

an icosahedral capsid and an envelope

Electron micrographs,
incomplete

viral

however,

particles,

(158, 174).

have demonstrated the presence of many
which

complement of viral DNA (103, 174).

may

contain

less

than

the

full

In addition, there are "dense bodies",

which appear to be composed of excess viral structural proteins surrounded
by an envelope.

The dense bodies carry HCMV-specific antigens but have

no detectable DNA (137,159).
to plaque-forming units

Thus, the ratio of non-infectious particles

(pfu)

resulting from HCMV infection may be as

great as 100: 1.
The replication steps of HSV and HCMV also have been compared by
electron microscopy.

Both viruses enter cells by phagocytosis or fusion

with the plasma membrane.
perinuclear

area,

but

HCMV

Both rapidly traverse the cytoplasm to the
nucleocapsids

appear

to

acquire

a

fine

fibrillar coat in the cytoplasm and are subsequently disassembled much
more slowly than HSV nucleocapsids (141).
therefore,

Adsorption and penetration,

occur equally rapidly in both HSV and HCMV infections,

but

replication of HCMV DNA proceeds at a much slower rate than that of HSV
(38,169,142).
Another

difference between HSV and HCMV

is

that HSV

infection

rapidly shuts down host macromolecular synthesis while HCMV infection in
permissive cells may stimulate the synthesis of cellular macromolecules
(37).
the

The physiological state of the permissive cell, however, affects

amount

replication.

of cellular DNA synthesis
Subconfluent

cells

infection than are confluent cells.

are

as well
much

as

more

the

amount of HCMV

susceptible

to

HCMV

It was demonstrated by DeMarchi and

5

co-workers (37), however, that stimulation of cellular DNA synthesis only
occurred in abortively infected cells, while DNA synthesis in productively
infected cells was eventually inhibited.

The rate of inhibition of DNA

synthesis is much slower than that which occurs in RSV-infected cells.
Molecular characteristics of HCMV DNA.

The size of the infectious

HCMV genome is approximately 240 kilobase (kb) pairs, but there is some
variation among strains (38,57,90).

Replication of full-length genomes

requires inoculation of permissive cell monolayers at a multiplicity of
infection (MOI) of 0.1 or less.

When the MOI is greater than 0.1, there

is an increase in production of defective genomes of less than 240 kb in
size (161).
The structure of the HCMV genome is similar to that of HSV 1 and 2.
There is a long unique sequence (UL) bounded by inverted repeats (IRL) and
a shorter unique sequence (Us) also bounded by a different set of inverted
repeats

(IRS)

(Figure

1).

The

presence

of

submolar

fragments

in

restriction endonuclease digests of the viral DNA supports a model in
which there are four possible genome arrangements.

Inversion of each

unique sequence and its repeats relative to the other produces the four
structures, which are present in approximately equal amounts in infected
cells (67,87,116,165).
Restriction

endonuclease

cleavage

patterns

and

nucleic

acid

hybridization techniques have been used to determine strain variation of
HCMV

(78,147,164).

Strains

of

HCMV

from

the

same

species

approximately 80% or greater homology at the DNA level (78,126).

show

A study

of several strains of HCMV demonstrated, that in spite of loss or gain of

6

Figure 1.

The structure of the genome of HCMV.

The four arrange-

ments are generated by the ability of each unique sequence and its
associated repeats to invert in relationship to the other.

IRL

long inverted repeat sequence

IRS

short inverted repeat sequence

UL

long unique sequence

Us

short unique sequence

I~

a

b

a

b

d

c

b

a

d

c

b

8
restriction endonuclease

sites,

the

order of homologous

fragments

is

colinear for all of these strains (26,172).
Digestion of

the

DNA of HCMV

strains with

several

endonucleases produces strain-specific "fingerprints"
al.

restriction
Huang et

(150).

(78) studied a group of women and their infants who had evidence of

HCMV infection.

The patterns of DNA restriction fragments of mother and

offspring were identical for at least two restriction enzymes (BamHI and
HindIII) and showed only minor changes in band migration with a third
enzyme (EcoRI).

Unrelated controls carried heterogeneous strains of HCMV

with

restriction

different

patterns

for

all

three

enzymes.

Repeat

isolates from some of the same patients over a period of as long as nine
years had the same restriction pattern as the initial isolate.
of

the

apparent

strain

stability,

however,

there

is

In spite

as

yet

no

classification of HCMV similar to that of HSV, which can be separated into
two types by both antigenic and molecular criteria (87,158).
A characteristic that HCMV does have in common with HSV is temporal
expression of the viral genome (38,160,168,169).

Three groups of virus-

specific proteins have been described based on their order of production
in the infected cell.
viral

protein

Immediate early proteins

synthesis

for

their

expression

(IE)

require no prior

and

are

produced

in

lytically-infected cells after treatment with protein synthesis inhibitors
or in abortively-infected cells (109,162,163).

There is a switch from IE

proteins

hours

to

early

lytically-infected

(E)

proteins

cells.

Early

within

two

proteins

do

not

post-infection
require

viral

in
DNA

synthesis, and they are produced in the presence of viral DNA replication

9

inhibitors.
(6,81).
are,

Some E proteins are also produced in latently-infected cells

Late (L) proteins require viral DNA synthesis for expression and

therefore, not produced in nonpermissive,

abortively or latently-

infected cells (55,63,102).
Another characteristic of HCMV replication is that the temporal
expression of the genome is frequently controlled posttranscriptionally
(55,146).

HCMV

early

and

late

messages

are

both

present

early

in

infection, but the messages are not translated until the appropriate time.
There are therefore, several factors which influence the outcome of
HCMV infection;

1) the type and species of cell; 2) the physiological

state of the cell (8,35,37); and 3) the temporal expression of the viral
genome (38,160,163,169).

Both cellular and viral regulatory proteins,

involved in the temporal control may be responsible for the prolongation
of

the

HCMV

lytic

cycle

and

for

the

determination

of

latency

or

persistence in non-lytic infections (8,169).
Epidemiology.

Evidence of HCMV infection is widespread.

Detectable

antibody titers and active virus excretion can be demonstrated in a high
percentage of members of various socially-defined groups.

From 20 to 60%

of children in day care centers shed virus in their urine (1,84,118).

Up

to 2% of newborns are infected congenitally (69,154).

Between 20 and 80%

of

(43,170,173),

the

general

adult

population

is

seropositive

seropositivity can be as high as 95% in homosexual men (28).
infections

are

asymptomatic,

but

serious

complications

may

but

Most HCMV
occur

in

neonates or in immunocompromised hosts (120,131,155,156).
Congenital infection is defined by isolation of virus from patient

10
specimens taken during the first week of life (11,156,176).
of the virus

appears

to be

predominately a

The source

reactivation of maternal

infection, although occasionally primary maternal disease occurs during
pregnancy.

Symptoms range from persistent viruria to death.

The severity

of the symptoms is greatest with primary maternal infection, but factors
such as gestational age at the time of infection and the immune response
of

the

may

fetus

contribute

also

to

the

clinical

outcome

(10,119,120,154,155).
Perinatal

infection

is

also

usually

maternal

in

origin,

but

nosocomial sources may produce disease in some cases (39,69,148).

The

maternal infection is again generally a reactivation of latent virus and
is passed to
(75,131).

the

infant through the genital tract or in breast milk

Many of these infants shed virus asymptomatically, but in some

cases the children have neurologic sequelae even though they are initially
asymptomatic.

Slow psychomotor development and loss of hearing may become

apparent at a later age (131,170).
Current
association

interest

with

blood

(16,17,66,105,153),
(43,44,149).

in

the

pathogenicity

transfusion

of HCMV

(2, 85, 125),

organ

from

its

transplantation

and the acquired immune-deficiency syndrome

(AIDS)

Cytomegalovirus infections under these conditions usually

are caused by endogenous reactivation of latent virus,
transplant

stems

and blood

transfusion recipients

however,

may also be

organ

infected by

reactivation of latent virus present in the exogenously-acquired tissue.
HCMV has been recovered from peripheral blood leukocytes (41,175),
which

are

probably

the

source

of

post-transfusion

HCMV

infection.

11

Multiply-transfused patients show a higher rate of seroconversion, which
is further evidence of transmission of HMCV through blood products (2).
It would appear,

therefore,

However,

transmission.

that donor blood can be a source for HCMV

there is evidence that reactivation of latent

virus can occur following transfusion.

When viral isolates from a group

of donors and recipients were compared by DNA restriction endonuclease
analysis,

the paired isolates

appeared to be unrelated.

(76).

Most

patients remain asymptomatic, but neonates and immunosuppressed patients
are vulnerable to adverse sequelae (85).
Organ transplant recipients are highly susceptible to HCMV infection
In

(62,123).

many

cases

the

source

of

the

virus

is

probably

a

reactivation of latent host infection, but transmission of virus from the
donor

organ has

analyzed

viral

been frequently
DNA

from

renal

documented

(16, 105, 166).

donor-recipient

restriction enzyme fragment polymorphisms.

paired

Chou
isolates

(16)
for

Seropositive recipients were

found to shed virus of donor origin in some cases,
different from those of the donors were also recovered.

but viral strains
The donor strain

was detected in isolates from seronegative recipients.
In a series of cardiac transplant patients (123) the donors were
demonstrated
seronegative.

to

be

the

source

of

HCMV

when

the

recipients

were

These recipients had primary HCMV infections from latent

or infectious virus present in donor tissue or contaminating blood.

The

recipients who were seropositive for HCMV before transplantation, and who
subsequently developed HCMV viremia, most likely had a reactivation of
latent host virus.

12
Finally, HCMV infection is found in close to 100% of patients with
AIDS (42,44,52).

A significant number of these patients may experience

severe HCMV infection in the form of retinitis,
HCMV

may

cooperatively

enhance

immunodeficiency virus (HIV).
HCMV

the

colitis or pneumonia.

pathogenicity

Nelson et al.

patients

interaction,

HCMV

however,

infection is

most

the

The mechanism of
In these

has not been determined.
frequently

human

(110) reported that HIV and

can co-infect brain cells in patients with AIDS.

synergistic

of

a

reactivation of

latent

infection, because the majority of the patients are seropositive for HCMV
at the onset of AIDS (45,68).
Latency

and

oncogenicity.

Since

reactivation

of

latent

HCMV

infection appears to be a significant factor in the pathogenesis of the
virus, there have been a number of studies to determine the site of the
latent infection.
seem

to

be

Polymorphonuclear and adherent mononuclear leukocytes
the

(32,41,83,114,132,139).

most

likely
In

situ

sources

of

hybridization

inactive

virus

experiments

have

demonstrated the presence of viral DNA and RNA in both of these cell types
in the peripheral blood.

Human lymphocytes and monocytes can be infected

with HCMV in vitro, but this results in abortive infection (132).

Factors

which may trigger activation of the virus include infection with another
agent (43,52), host immunosuppression (85) or host response to allogenic
cells (17,114).
There is evidence that HCMV may also be oncogenic (19,108).

Three

transforming regions of the genome of strains AD169 and Towne have been
mapped to the UL (XbaI C fragment of AD169).

Each of these is designated
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as

a

morphological

transforming

region

(mtr),

which

is

neoplastic transformation of established rodent cell lines.
a non-coding region, which can transform NIH 3T3 cells.

capable

The mtrI is

The sequence can

form a stem-loop structure similar to an insertion element (109).
mtrII and mtrIII transform rodent cell lines (47).

of

Both

There are open reading

frames in mtrII in addition to potential stem-loop strutures (130).

No

transforming proteins have been identified. Transcriptional activation or
genetic rearrangement by HCMV DNA elements may be responsible for cell
transformation.
In a recent study (7) it was reported, that HCMV infection activates
the proto-oncogenes c-fos, c-jun and c-myc.

Increased production of all

three proto-oncogene mRNAs was noted as an immediate early event in HCMV
infection.

Inactivated virus was still able to cause an increase in the

proto-oncogene mRNA levels, therefore, viral protein synthesis was not
required.

It was postulated that interaction of the virus with the cell

surface might be

the mechanism of activation,

but the

role of this

activation in HCMV oncogenesis remains speculative.
Susceptibility to Antiviral Agents.

Another factor which adds to

the seriousness of HCMV infection is the resistance of this virus to many
antiviral agents including acyclovir (ACV).

One agent which has proven

effective in treatment of severe HCMV infection is 9-(1,3-dihydroxy-2propoxymethyl)guanine (DHPG).

DHPG is now more commonly referred to as

ganciclovir or GCV.
GCV has been used experimentally to treat severe HCMV infections
especially in transplant or AIDS patients (27,24,94).

It is currently
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approved for treatment of HCMV retinitis.

Most clinical and laboratory

strains remain sensitive to GCV (106,122), but increased resistance has
been reported among both types of isolates (4,24,48).

Neutropenia is a

side-effect of GCV treatment, which limits the usefulness of this drug for
some patients (94).
A second antiviral
inhibitory
foscarnet)
this

activity
(167).

agent.

agent which has

against

HCMV

is

been clinically

phosphonoformic

tested

acid

(PFA

for
or

There are also adverse side-effects associated with

Manischewitz

et

al.

(99)

demonstrated

a

synergistic

inhibition of HCMV by GCV and PFA for both clinical isolates of HCMV and
the laboratory strain AD169.

Both drugs inhibit viral DNA polymerase

activity, but the target site within the polymerase is probably different
for each drug.

In addition the toxicities of GCV and PFA differ. The

synergy might allow treatment with lower doses of each drug, and thus,
minimize the adverse side-effects of the individual agents.
In addition to treatment of HCMV infections antiviral agents have
been used in the selection and isolation of resistant mutants.

Viral

genes related to drug activity can be mapped from these mutants. The HSV1 DNA polymerase coding sequence was
manner (20,58,71,72,88,127).
include

phosphonoformic

acid

functionally determined in this

Agents whose target is the DNA polymerase
(PFA)

(112),

(40,74) and aphidicolin (Aph) (80,111).

phosphonoacetic

acid

Several other agents which target

the polymerase also must be activated by cellular or viral kinases.
these agents are

(PAA)

9-~-D-arabinofuranosyladenine

Among

(Ara A) (22), 5'-iodo-2'-

fluoroaracytosine (FIAC), 5'-iodo-2'fluoroarauracil (FIAU) (25,100), ACV
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( 9 3,138) and GCV (15,31,50,53,143).
( 30).

Cellular enzymes phosphorylate AraA

FIAC, FIAU, ACV and GCV are monophosphorylated in HSV-1-infected

cells by the viral TK.

These agents are only phosphorylated at low levels

by the cellular TK (5,25,30).

Di- and tri-phosphorylation is thought to

be carried out by cellular enzymes.

This means

that drug-resistant

mutants of the virus may be separated into two classes:

1) thymidine

kinase mutants in which the enzyme fails to phosphorylate the drug and
2) polymerase mutants in which the altered enzyme is no longer a target
for the drug.

Both types of mutants have been described for HSV-1

(23,93,138).
Although cellular thymidine kinase activity is increased in HCMVinfected cells, no viral thymidine kinase activity has been demonstrated
(49,53,177).

The fact that HCMV is sensitive to GCV, however, suggests

that monophosphorylation of this drug in HCMV-infected cells requires a
viral function. In addition there is evidence, that the cellular thymidine
kinase activity induced by HCMV infection is completely separable from the
"GCV kinase" activity (4,5,53).

Therefore, there also may be two classes

of HCMV GCV-resistant mutants.
There have been only two reports of HCMV drug-resistant mutants.
D'Aquila and Summers (34) isolated PAA-resistant mutants and Biron et
al.(4) characterized a GCV-resistant mutant.

In both cases the mutants

were selected by growing the wild-type virus in increasing concentrations
of the drug.

Unlike HSV there have been no one-step high-level drug-

resistant mutants of HCMV reported to date.
Rapid detection of HCMV.

The potentially severe consequences of
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HCMV

infection

and

the

availability

diagnosis desirable (133).

of

antiviral

agents

make

rapid

Cell culture is usually very slow, but it is

still the standard identification method for comparison with newer more
rapid techniques.

Two techniques which show the most promise for rapid

viral identification are:
antibodies,

and 2)

1) detection of viral antigens with monoclonal

hybridization of viral nucleic acids with labeled

probes.
Monoclonal antibodies specific for HCMV are available commercially.
Detection of infected cells by immunofluorescence is now widely used in
conjunction with cell culture (61,82,96,101,145).

The sensitivity of the

method is still not high enough to detect all HCMV-positive specimens, but
for

screening purposes

it

is very useful.

immunofluorescence method is

that

One

disadvantage

it still requires

of

the

cell culture for

antigen amplification.
The use of DNA probes for detection of HCMV can be applied directly
to

clinical

specimens.

(11,18,140,150,151),
hazardous.

but

Probes
the

labeled

isotope

has

with
a

short

32

P

are

sensitive

half-life

and

is

Nonisotopically-labeled probes have been developed to avoid

these problems (9,12,92,95,97,107), but the sensitivity has

been lower

as compared to that of the radioactive probes.
Amplification of probe target sequences by the polymerase chain
reaction (PCR) has improved significantly the sensitivity of hybridization
methods (13,73,115).

Selection of primers, however,

is critical, since

variation in clinical isolates may prevent primer binding and subsequent
amplification.

Hsia et al.(73) used two sets of primers homologous to
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sequences at opposite ends of the genome.

The PCR amplification produced

positive results in all culture-positive specimens.

Olive et al.

(115)

reported that the PCR method of detection in clinical samples was only
positive when the same sample was scored as positive with at least one
other method (culture, immunofluorescence or direct probe hybridization).
The assay has, therefore, been reported to be as sensitive as cell culture
and results are available rapidly.
It is apparent that there have been recent advances in detection
and treatment of HCMV infections.

These advances are in large part the

result of a better understanding of the molecular biology of both HSV and
HCMV.

Detection methods are based on characterization of both virus-

specific antigens and selected regions of the DNA genome.
antiviral agents

requires

an understanding of the

The design of

function of virus-

specific proteins and the transcriptional and translational control of
their expression.

Knowledge of the genome organization and viral products

of HSV has provided a basis for many of the experiments for HCMV.

HCMV

is a much more difficult viral system to work with than HSV, and for this
reason the level of understanding of the mechanisms of HCMV pathogenesis
still lags behind that of HSV.

MATERIALS AND METHODS

Virus.

HCMV strain AD169 (134) was obtained from Dr. Marc Beem at

the University of Chicago.
were

collected from

Clinical isolates of HCMV, HSV-1 and HSV-2

the

Clinical

University Medical Center.

Microbiology

Laboratory

at

Loyola

Additional clinical isolates of HCMV were

collected by Dr. Mary Christensen, Childrens Memorial Hospital, Chicago,
IL.
Virus

stocks

were

frozen

and maintained at

- 70° C in medium

containing 10% dimethylsulfoxide (DMSO) and 10% fetal calf serum (FCS).
Stocks were propagated by inoculation of permissive cell monolayers at an
MOI

of

0.01-0.001.

Virus

stocks

were

harvested

3 days

after

the

appearance of 100% CPE.
Cells.

Human foreskin

fibroblasts

(HFF)

at passage

5- 7 were

purchased from Bartels, Bellevue, WA, and maintained in Eagle's minimum
essential medium (MEM) (Hazelton, Denver, PA or Gibco, Grand Island , NY)
supplemented with 1% FCS (Gibco), 7.5% NaHC03 (to adjust pH to 7.2), Lglutamine (1 mM), HEPES buffer (20 mM) (Flow Laboratories, Mcclean, VA),
gentamicin

(50

µg/ml)

(M.A.

Bioproducts.

amphotericin B (Gibco) (2.5 µg/ml).

Walkersville,

MD)

and

Confluent monolayers were passaged

1:2 and grown to confluency in Eagle's MEM containing the same supplements
except 10% FCS.

Earles balanced salt solution (EBSS) (Flow Laboratories)

was used for washing cell monolayers.
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Mycoplasma testing.

Virus stocks of AD169 and mutant D6/3/l were

tested for mycoplasma contamination by culture on Mycotrim RS and Mycotrim
GU triphasic medium (Hana Biologics, Inc. Almeda, CA).

In addition HFF

monolayers inoculated with each stock were sent to Program Resources,
Inc., McClean VA (formerly Flow Laboratories) for more extensive testing.
This testing included Hoechst staining of infected cells,

monoclonal

antibody fluorescent staining specific for !:L.. hyorrhinis, and culture of
both cell culture fluid and cells.
Antiviral

agents.

All

antiviral agents were

reconstituted in

distilled water except for aphidicolin, which was reconstituted in 10%
DMSO.

The stocks were filtered through a 0.2 µm filter for sterility.

The following is a list of the agents and manufacturers:
1) Adenine 9-fi-D-arabinofuranoside (AraA); thyrnine-1-D-arabinofuranoside

(AraT);

aphidicolin

(Aph);

phosphonoacetic acid

phosphonoformic acid (PFA) all from Sigma,

(PAA)

and

St. Louis, MO.

2) 5-iodo-2'-fluoroarauracil (FIAU); 5-iodo-2'-fluoroaracytocytosine (FIAC) both a gift from Bristol-Myers, Wallingford, CT.
3) Acyclovir (ACV) from Burroughs Wellcome, Research Triangle
Park, NC.
4)

Ganciclovir

(GCV)

a gift

from Burroughs -Wel lcome,

Research

Triangle Park, NC and Syntex, Palo Alto, CA.
Plague assay.

The method of Wentworth and French (171) was modified

for titering and plaque purifying virus.

HFF cells were grown to 80-90%

confluency in 24-well tissue culture plates.

Ten-fold viral dilutions

were made in maintenance medium for inoculation.

Growth medium from the
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wells was removed and replaced with 0. 1 ml inoculum.
allowed to adsorb for 2-4 hat 37° C.

The virus was

The inoculum was removed at the end

of the adsorption period and replaced with an overlay of equal parts 0.6%
agarose and double strength maintenance medium.

Seven days later a second

overlay of the same composition was placed on top of the first.

Fourteen

days were usually required for reading of titers and plaque purification.
Extraction and purification of viral

DNA.

Virus

stocks were

propagated in either tissue culture flasks (150 cm2 ) or roller bottles
(850 cm2 ). Each monolayer was inoculated at subconfluency at an MO! between
0.1 and 0.01.

The supernatant was harvested 3 days after 100% CPE was

observed.
A modification of the method of La Femina and Hayward (91) was used
to extract the DNA.

Infected cell culture fluid was centrifuged at 7,000

rpm for 10 min in a Sorvall GSA rotor.

The supernatant was centrifuged

at 12, 000 rpm for 90 min in the same rotor.

The pelleted virus was

resuspended in a buffer containing 0.1 M NaCl, 0.01 M Tris-HCl pH 8.0,
0.01 M EDTA.

Heat-treated RNase A (20 µg/ml) was added to the virus

suspension, which was then incubated at 37° for 60 min.

Sarkosyl (2%) and

SDS (0.5%) were added, and the lysate was incubated at 37° C for 60 min.
Predigested Pronase
overnight.

After

(1 mg/ml) was added and incubation was continued
extraction with

phenol:chloroform:isoamyl

alcohol

(50:48:2) the aqueous layer was precipitated with two volumes of ice-cold
95% ethanol.

The precipitated DNA was centrifuged and DNA pellets were

redissolved in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA).
Cloned restriction fragments.

Approximately 1 µg of HCMV strain
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AD169 DNA was digested to completion with BarnHI.
linearized

with

BarnHI.

The

digests

were

The vector pBR322 was

ethanol

precipitated

and

redissolved in ligase buffer (60 mM Tris-HCl pH 8.0, 33 mM NaCl, 10 mM
MgC1 )
2

containing ATP

(0. 5 mM)

and DTT

(5mM).

The ligation reaction

mixture contained the precipitated digests of insert (HCMV) DNA and vector
(pBR322) DNA at a concentration ratio of 10:1 and 1 unit of T4 ligase.
The

streptomycin-resistant E_.

hsdM-, recB, recC,

coli

strain SF8

[genotype:

lop-11 (ligase overproducer) supE44),

hsrR-,

gal-96, leuB6,

thi-1, thr; a gift from Dr. Masayasu Nomura, University of Wisconsin] was
grown in an overnight preculture in 5 ml of Luria broth (Gibco).

A 0.2

ml sample of this preculture was added to 20 ml of Luria broth and grown
to a Klett reading of 100.

The bacteria were sedimented by centrifugation

at 5,000 rpm in a Sorvall SS-34 rotor for 5 min at 2° C.

The pelleted

cells were resuspended in 10 ml cold 50 mM CaC1 2 and incubated for 60 min
at 0° C.

The centrifugation and resuspension steps were repeated in a 1

ml volume of CaC1 2 .

The bacteria were then added in a 2:1 (v/v) ratio to

the ligation mixture.

The transformation sample was incubated for 2 min

at 37° C for 20 min.

Dilutions of the cells from the sample were then

plated out on Luria agar plates containing ampicillin
tetracycline

(10 µg/ml).

(100 µg/ml)

or

Colonies which appeared on the plates were

numbered and picked to duplicate plates containing either ampicillin or
tetracycline.
to

Colonies which were resistant to ampicillin but sensitive

tetracycline

were

selected for

further

plasmid analysis.

Insert

fragments were identified by restriction endonuclease digestion patterns
based on

the map

published by Greenaway

et

al

( 6 7) .

There

are

67
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recombinant clones which compose a partial HCMV AD169 genomic library.
EcoRI restriction fragments of HSV-1 strain KOS DNA inserted in the
vector pBR328 were kindly provided by Dr. Myron Levine, University of
Michigan, Ann Arbor.

In particular pSG17 and pSG87 (64) containing the

HSV-1 EcoRI M and N fragments respectively were used as radiolabeled
probes.
Plasmid DNA Isolation.

Large-scale plasmid isolation was performed

by the alkaline lysis method described by Maniatis (98).

A 5 ml Luria

broth preculture containing 100 µg/ml ampicillin was inoculated with the
recombinant bacterial strain and incubated at 37° C with shaking overnight.
The bacteria were harvested by centrifugation at 7,000 rpm for 10 min at
4° C in a Sorvall GSA rotor.

The pellet was resuspended in 5 ml of a

solution containing 50 rnM glucose, 25 rnM Tris-HCl pH 8.0, 10 rnM EDTA and
transferred to a 50 ml Oak Ridge tube.

An additional 5 ml of the same

solution containing 10 mg/ml lysozyrne was added and the suspension was
incubated at room temperature for 5 min.

Then 20 ml of a freshly-made

solution containing 0.2 N NaOH, 1% SDS was added and incubation at room
temperature was continued for 10 min.

The tube was filled with an ice-

cold solution of SM potassium acetate (pH 4.8). The tubes were vigorously
shaken and placed on ice for 10 min.

The tubes were centrifuged at 18,000

rpm for 30 min at 4° C in a Sorvall SS34 rotor.

The supernatant was

divided into two 30 ml Corex tubes and 0.6 volumes of isopropanol was
added.

The tubes were incubated at room temperature for 15 min and

centrifuged at 10,000 rpm for 30 min also at 20° C in the SS34 rotor.
pellets were resuspended in 7.4 ml TE.

The

To purify the plasmid DNA, 1 g
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csCl and 0.8 ml ethidium bromide (lOmg/ml) were added per ml of sample
volume.

The samples were centrifuged in a Beckman VTi 6S rotor at 60,000

rpm or a Beckman Tl-100 rotor at 86,000 rpm for 16-20 h.
were harvested from the gradients by side puncture.

Plasmid bands

The ethidium bromide

was removed by extraction with isopropanol saturated with lOX SSC (lX SSC
is O.lS M NaCl, O.OlS M trisodium citrate).

The DNA was precipitated by

adding an equal volume of TE to reduce the salt concentration and then
adding

two volumes

overnight.
at 4° C.

of ethanol.

The

samples were placed at

- 20° C

DNA was pelleted by centrifugation at 10,000 rpm for 20 min
Pellets were resuspended in TE.

For rapid small-scale plasmid isolation a l.S ml culture in Luria
broth (Gibco) with 100 µg/ml ampicillin was incubated at 37° with shaking
overnight.

Samples were centrifuged for 1 min in a microcentrifuge.

The

pellets were resuspended in 100 µl of an ice-cold solution containing SO
rnM glucose, 10 rnM EDTA, 2S rnM Tris-HCl pH 8.0, and 4 mg/ml lysozyme.

The

suspensions were incubated for S min at room temperature, and then 200 µl
of fresh solution containing 0.2 N NaOH, 1% SDS was added followed by
another incubation for

S min at room temperature.

A lSO µl volume of

ice-cold SM potassium acetate solution pH 4.8 was added, and the samples
were placed on ice for S min then centrifuged for S min at 4° C in a
microcentrifuge.

The supernatant was removed to a fresh tube and an equal

volume of phenol: chloroform: isoamyl alcohol (SO: 48: 2) was added.
samples were centrifuged for S min at 4° C.
to a fresh tube.

The

The aqueous layer was removed

The DNA was precipitated with 2 volumes 9S% ethanol at

room temperature and pelleted by microcentrifugation.

The pellets were
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washed with 70% ethanol and re-centrifuged.

The pellets were dried and

resuspended in 30 µl TE (lOmM Tris-HCl pH 7.5, 1 mM EDTA) containing 20
µg/ml RNase A.
Agarose gel electrophoresis.

Both undigested and restricted DNA

samples were routinely analyzed by electrophoresis on horizontal 0. 7%
agarose gels in buffer containing 89 mM Tris base and boric acid, and 2

mM disodium EDTA (final pH 8.0).

After electrophoresis,

the gels were

stained with 0.5 µg of ethidium bromide per ml of staining solution.
Removal

of

insert

DNA

from

recombinant

plasmids.

Recombinant

plasmid DNA was digested with the appropriate restriction endonuclease.
Insert DNA was separated from vector DNA by agarose gel electrophoresis,
electroeluted from the gel and purified by passage over a DEAE-Sephacel
(Pharmacia,

Piscataway,

NJ)

column (98).

The DNA was eluted from the

column with buffer containing 10 mM Tris-HCl pH 7.5,

1 mM EDTA,

0.6 M

NaCl, and concentrated by ethanol precipitation.
Alternatively restriction fragments were removed from low melting
point

(LMP)

agarose

Gafner et al.

(54).

(FMC BioProducts,
Briefly,

Rockland,

ME)

by the method of

the agarose containing the fragment was

heated at 65° C, extracted twice with phenol equilibrated with 50 mM TrisHCl pH 8.0 and once with chloroform.

The DNA was concentrated by ethanol

precipitation.
Processing of clinical specimens for probe detection of HCMV DNA
(18,152).

Clinical urine specimens were kindly collected by Dr. Mary

Christensen at Children's Memorial Hospital,
ranged from 1 to 3 ml.

Chicago,

IL.

The volumes

The total volume was brought up to 8 ml with EBSS

25
without indicator.

The samples were centrifuged at 2,000 x g for 5 min.

In some samples, a portion of this low-speed-centrifugation pellet was
examined for cells, crystals, and bacteria.

The pellet was then returned

to the supernatant, and the total sample was centrifuged at 25,000 x g for
90 min.

Alternatively the supernatant from the low-speed centrifugation

was transferred to a new tube and centrifuged at 25,000 x g for 90 min.
A 20-µl volume of a solution containing 0.1 M NaCl, 10 mM Tris-HCl
pH 8.0, 10 mM EDTA, 500 µg of pronase per ml, and 0.5% SDS was added to
the pellets

from the high-speed centrifugation,

incubated at 3 7° C for 1 h.
microcentrifuge tubes,
chloroform-isoamyl

and this mixture was

The samples were transferred to 1. 5 ml

extracted twice with an equal volume of phenol-

alcohol

(50: 48: 2),

extracted once with chloroform-

isoamyl alcohol (24:1), and precipitated with ethanol.
were suspended in 20 µl of TE.

The precipitates

An equal volume (20 µl) of 0.3 M NaCl/1.0

M NaOH was added; the samples were vortexed briefly and allowed to stand
for 15 min at room temperature. Another volume (40 µl) of 0.8 M Tris-HCl
pH 6.8/lM NaCl was added.
Minifold

filtration

The entire sample was placed in a well of a

apparatus

(Schleicher

&

Schuell,

blotting onto a nitrocellulose filter (BA85, Schleicher

Keene,

&

NH)

Schuell).

slight vacuum was applied after the wells appeared to be empty.
nitrocellulose filter was baked under vacuum at 80° C before

for
A
The

further

processing.
Samples of HCMV, HSV-1, and HSV-2 were processed in the same manner
as

were

the

clinical

samples.

suspended directly in 20 µl

DNA from

each

of

these

viruses

was

of TE and prepared for dot blotting onto
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nitrocellulose filters as described above.
Processing of infected cell monolayers for probe detection of HCMV

RNA

(151,152).

Cell culture fluid was removed and the monolayers were

washed with 2 ml EBSS.

Monolayers were detached after washing by adding

250 µl of a filtered 0.25% trypsin solution and incubation at 37° C for
5 min.

One milliliter of EBSS without indicator was added to each tube.

The samples were transferred to 1.5 ml microfuge tubes and centrifuged at
5,000 x g for 5 min.

The supernatant fluid was discarded.

The cell pellets were treated with 200 µl of lysis solution (100 mM
NaCl, 10 mM Tris-HCl pH 8.0, 10 mM EDTA, 500 µg/ml pronase and 0.5% SDS)
and incubated at 37° C for 1 h.

The lysate was extracted twice with

phenol:chloroform:isoamyl alcohol, once with chloroform:isoamyl alcohol
(24:1) and ethanol precipitated.
TE.
were

The pellets were redissolved in 20 µl

An equal volume of 1 M NaOH-2 M NaCl was added, and the suspensions
incubated at

room

temperature

for

15 min.

neutralized with 40 µl of 3 M sodium acetate pH 5.5.

The

samples

were

Each sample was

suctioned onto either a GeneScreen Plus membrane (DuPont NEN, Boston, MA)
or a nitrocellulose filter using a Minifold filtration apparatus

as

described above.
Labeling of DNA probes.

Two methods were used to label DNA probes.

DNA for biotinylated probes was labeled with biotinylated dUTP by nick
translation with reagents purchased in a kit manufactured by BRL.

The

labeled probes were separated from unincorporated nucleotides by ethanol
precipitation.

Some radioactive probes were also labeled with 32 P-dCTP by

nick translation using the same BRL kit, but unincorporated nucleotides
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were

removed

by

Sephadex

G-50

chromatography.

The

Sephadex

G-50

(Pharmacia) was equilibrated in buffer containing 50 mM Tris-HCl, 10 mM
EDTA.

The nick translation mixture was loaded onto the column and the

same buffer was

used

to

elute

the

probe.

Separation of probe

unincorporated nucleotide peaks was monitored with a
Approximately

1.5

ml

of

buffer

containing

the

and

Geiger counter.

separated

probe

was

collected directly after the predetermined void volume.
More recently,

smaller quantities of DNA (25 ng) were labeled by

random priming with a kit purchase from Amersham, Arlington Heights, IL.
The unincorporated nucleotides were separated from the labeled probes by
spin columns purchased from 5 Prime-->3 Prime, Inc., West Chester, PA.
Southern hybridizations.

Agarose gels were prepared for Southern

blotting by depurination in 0.4 M HCl, denaturation in 0.5 M NaOH-1.0 M
NaCl and neutralization in 0.5 M Tris-HCl-1.5 M NaCl.

The gels were

blotted onto GeneScreen Plus or Nytran (Schleicher and Schuell) with lOX
SSPE (lX SSPE is 0.18 M NaCl, 10 mM NaH 2P04 , 1 mM EDTA).
were prehybridized in 50% formamide,

0.9% SDS,

5X SSPE,

The membranes
lOX Denhardt's

(lX Denhardt's is 0.02% Ficoll, polyvinylpyrrolidone and BSA) and 50 µg/ml
salmon sperm DNA for 1-2 h at 42° C.

The prehybridization solution was

replaced with hybridization solution containing 6X SSPE,

1% SDS,

formamide, and 50 µg/ml salmon sperm DNA and heat-denatured probe.

50%
The

membranes were hybridized overnight at 42°.
Gene Screen

Plus

manufacturer's protocol:

membranes

were

washed

according

to

the

twice with 100 ml 2X SSC at room temperature

for 5 min each; twice with 200 ml 2X SSC/1% SDS at 65° for 30 min each;
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twice with 100 ml O.lX SSC at room temperature for 30 min each.
membranes were washed as follow:

Nytran

once in lX SSPE for 5 min at room

temperature; twice in lX SSPE/1% SDS at 65° C for 15 min each; twice in
O.lX SSPE at room temperature for 15 min each.

Membranes were briefly

air-dried and placed

Cronex Lightning Plus

in X-ray cassettes with

intensifying screens (DuPont, Wilmington, DL) and Kodak X-OMAT AR film.
The cassettes were held at -70° C for whatever period of time was required
for the individual experiment.
Dot-blot hybridization.

Dot-blotted nitrocellulose filters were

prehybridized in a solution containing 45% formamide, 5X SSC, 0.2% BSA,
0.2% ficoll 400, 25 mM sodium phosphate buffer pH 6.5 and 300 µg/ml heatdenatured calf thymus DNA.

The filters were prehybridized in a heat-seal

bag at 42° C for 2 h with shaking.
The filters

were hybridized in a

solution containing the same

components as the prehybridization plus 0.1% sodium pyrophosphate, 10%
dextran sulfate (Pharmacia), and heat-denatured biotinylated probe.

The

filters were incubated in heat-seal bags at 42° C for 1-20 h depending on
the experiment.
After hybridization, nitrocellulose membranes were washed according
to the manufacturer's (BRL) protocol: twice in 2X SSC/0.1% SDS at room
temperature for 3 min each; twice in 0.2X SSC/0.1% SDS at 50° C for 15 min
each; once in 2X SSC/0.1% SDS at room temperature for 3 min.
Detection

of

hybridized

biotinylated

probe.

Membranes

were

rehydrated for 1 min in BRL Buffer I (100 mM Tris-HCl pH 7.5, 100 mM NaCl,
2 mM MgC1 2 , 0.05% Triton X-100).

The membranes were blocked for 20-75 min
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in freshly

prepared Buffer

II

(Buffer

I

containing

3%

After

BSA).

blocking, membranes were baked in a vacuum oven at 80° C for 20 min.
Membranes were rehydrated in Buffer II for 10 min and drained.
solution containing

2 µg/ml

Streptavidin in Buffer

I

was

pipetted over the membranes for 10 min at room temperature.

A

constantly
This was

followed by three washings in Buffer I at room temperature for 3 min each.
A solution containing 1 µg/ml

poly-alkaline phosphatase

(poly-AP)

in

Buffer I was pipetted over the membranes for 10 min at room temperature.
The membranes were then washed twice in Buffer I at room temperature for
2 min each and twice in Buffer III (100 mM Tris-HCl pH 9.5, 100 mM NaCl,
50 mM MgC1 2 ) at room temperature for 2 min each.

A dye solution (7.5 ml

Buffer III, 33 µl nitroblue tetrazolium (NBT), 25 µl 5-bromo-4-chloro-3indolyl phosphate (BCIP)] was added to the blocked membranes in a heatseal bag.

This step was performed in very low light, and the heat-seal

bag was placed in the

dark for

color development.

After 2 -4 h

the

reaction was stopped by washing the membranes in a solution containing 5

mM EDTA, 20 mM Tris-HCl pH 7.5 at room temperature for 15 min.
Standard strips spotted with low concentrations of biotinylated DNA
were baked for 2 h at 80° C in a vacuum oven.

A standard strip was

developed along with all test membranes.
Drug resistance measured by per cent survival.

Plaque-purified

isolates of each mutant were titered in the presence and absence of a
single

high

concentration

of

each

drug.

The

percent

survival

was

calculated from the ratio of the titer of each mutant in the presence of
the drug to the titer of the mutant in the absence of the same drug
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multiplied by 100.

The percent survival of the wild-type was determined

as a control for each experiment.
Drug-resistance measured by plague reduction.

The concentration of

each drug which could reduce the number of plaques of a single viral
dilution by fifty percent was determined.

All monolayers in a 24-well

plate were inoculated with a single viral dilution calculated to produce
30-50 plaques per control well.
medium

without

drug,

and

The four control wells were overlaid with

the

remaining

wells

were

overlaid

quadruplicate with medium containing a range of drug concentration.

in
The

assays were read at 14 days post-infection.
Drug-resistance
(ELISA) (3,128).

measured

by

enzyme-linked

immunosorbent

assay

Monolayers in 96-well microtiter plates were inoculated

with wild-type or mutant strains of HCMV at a single dilution.
wells were inoculated with maintenance medium.

Control

The inoculum was replaced

with medium containing two-fold dilutions of the drug.

In one set of

wells which had been inoculated with virus, the medium without drug was
added to serve as a virus control.

The plates were incubated usually for

5-7 days until the virus control demonstrated 50% CPE (2+).
In order to detect the amount of HCMV replication, the cell culture
medium was aspirated and replaced with 0.2 ml phosphate buffered saline
(PBS contains per liter: 7.65 g NaCl, 1.2688 g disodium phosphate, 0.1 g
monosodium phosphate, 0.2133 g monopotassiumphosphate) containing 1% BSA.
The plates were incubated at room temperature for 30 min.

The PBS-BSA was

aspirated and replaced with 0.2 ml per well ethanol:acetone 95:5, and the
plates were placed at

- 20° C for

30 min.

The

e thano 1 : ace tone was
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aspirated, and the wells were washed 5 times with PBT buffer (0.05% Tween
20 and 1% BSA in PBS).
(Nunc,

The washes were performed with an Immuno Wash 8

Kamstrup, Denmark).

DuPont NEN)

specific

for

Monoclonal antibody (Late Nuclear Protein,
an HCMV

late

antigen

(142)

was

added to

a

dilution of 1:5,000 in a solution containing 10% goat serum, 1% FCS, 0.05%
Tween 20 in a volume of 0.1 ml per well.

c

for 1 h.

The plates were incubated at 37°

The wells were again washed 5 times with PTB buffer, and 0.1

ml of goat anti-mouse lg conjugated with horse radish peroxidase (Bio-Rad,
Richmond, CA) at a dilution of 1:2,000 in a solution containing 10% goat
serum and 0. 05%

Tween

20 was

added to

each well.

The

incubated at 37° C for 2 h followed by 5 washes in PTB.

plates

were

A volume of 0.2

ml of substrate solution [2,2'-azinobis(3-ethylbenzthiazoline) sulfonic
acid (Sigma) and 0.005% H20 2 ] at a concentration of 1 mg/ml was added to
each well.

Color was allowed to develop for 15-30 min.

The plates were

read on a Dynatech MR580 Microelisa Auto Reader at 405 nm.
HPLC

analysis

of

GCV

anabolism

in

virus-infected

cells.

HFF

monolayers in 150 cm2 flasks were inoculated with HCMV AD169 or one of
the three GCV-resistant mutants (Dl/3/4, Dl0/3/2, D6/3/l) at an MOI of
approximately 1.0.

One flask was mock-infected for a cell control.

At

either 72 or 96 h post-infection 3H-GCV (a gift from Syntex, Palo Alto,
CA)

was

added to

approximately 1

each flask.

The concentration of labeled drug was

uM and cold drug was added such that

the

final

GCV

concentration was 50 µMand each flask contained approximately 1.67 x 10 7
cpm.
After 24 h incubation the cells were prepared for perchloric acid
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extraction.

The radioactive medium was removed from the HFF monolayers

and replaced with 1.5 ml 0.25% trypsin per flask to detach the monolayers.
An equal amount of growth medium was added to each flask, and the cells
were dispersed with a pipette.
centrifuge tube.
medium,

These cells were placed in a 15 ml conical

The flasks were washed with an additional 1.5 ml growth

which was

then added to

the

15 ml

tubes.

The

tubes were

centrifuged at 2,000 rpm in a Beckman TJ-6 tabletop centrifuge for 10 min.
All but 0. 5 ml of the supernatant was
resuspended in the remaining fluid.

removed,

and the cells were

The cells were transferred to a

microfuge tube, washed with 1.5 ml Dulbecco's PBS (DPBS per liter: 0.2 g
KCl, 0.2 g KH 2 P0 4 , 8 g NaCl, 2.16 g Na 2HP0 4 7H2 0).
1. 0 ml

DPBS

two more

times.

After the

The cells were washed in

final wash

the

cells were

resuspended in 200 µl DPBS, and 65 µl 2 M perchloric acid was added to
produce a final concentration of approximately 0.5% perchloric acid.

The

cell extracts were vortexed and then centrifuged for 20-25 min at 4° C. The
supernatant was transferred to a new microfuge tube and either placed on
ice for immediate analysis by HPLC or stored at -70° C.
GCV and GCV-monophosphate at a concentration of 100 rnM were used as
standards for HPLC analysis of products of infected-cell GCV anabolism.
These standards were injected in 10 µl volumes for analysis on a Partisil
10 ODS3 250 x 4.6 mm reversed phase HPLC column (Phenomenex, Rancho Palos
Verdes, CA).

The mobile phase was 0.02 M KH 2 P0 4 pH 3.65.

The perchloric

acid extracts of infected cells labeled with 3H-GCV were assayed under the
same conditions, but fractions were collected in scintillation vials at
0.3 min intervals for 15 min.

Scintillation fluid (10 ml Universal, ICN
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Biomedicals, Irvine, CA) was added to each vial, and each vial was counted
for 2 min on an LKB 1214 Rackbeta liquid scintillation counter.
Messenger RNA isolation from virus-infected cells.

Monolayers of

HFF in 150 cm2 flasks were inoculated at an MOI of 1.0 with wild-type
AD169 or mutant strains of virus.

Messenger RNA was isolated at 72 h

post-infection according to a kit protocol (Fast Track mRNA Isolation Kit,
Invitrogen, San Diego, CA).

Briefly, the cells were washed with DPBS and

lysed in Stock Buffer containing 0.2M NaCl, 0.01 M Tris-HCl pH 7.5, 1.5
M MgC1 2 ,

2% SDS plus 0.02 volumes RNase Protein Degrader

Invitrogen).

(patented by

The lysates were passed 5-6 times through a 21 gauge needle

to shear the cell DNA and then digested for 1-2 h at 45° C to remove
protein.

The salt concentration of the lysate was adjusted to 0. 5 M

before incubation with oligo dT for 40-60 min at room temperature.

The

oligo dT was washed repeatedly with a Binding Buffer [0.1 M EDTA, 0.01 M
Tris-HCl (diethylpyrocarbonate-treated)] and then added to a disposable
column.

Washing was continued until the OD 260 was less than 0.05.

poly A+ RNA was eluted with
M Tris-HCl)

The

kit-supplied Elution Buffer (0.5 M NaCl, 0.01

into four fractions of 0.4 ml each.

These fractions were

pooled, mixed and realiquoted into four microfuge tubes to ensure that the
mRNA concentration was the same in each tube.

The RNA was precipitated

at -20° C by adding 0.1 volume 2 M sodium acetate and 2 volumes of 100%
EtOH.

The

redissolved

samples were
in

50

µl

centrifuged for

TE.

The

OD 260

30 min at
was

taken

4° C,
to

dried

and

determine

the

concentration of RNA.
In vitro translation of mRNA from virus-infected cells.

Messenger

34
RNA isolated at 72 h post-infection from virus-infected or mock-infected
cells was used as a template for in vitro translation.

A micrococcal

nuclease-treated rabbit reticulocyte lysate (Promega) was used for the
translation.

The reaction mixture consisted of 35 µl of the lysate, 1 mM

amino acids minus methionine, 40 units of RNasin (Promega), 50 µCi 35 smethionine (DuPont NEN) and 5-10 µg of mRNA for a final volume of 50 µl.
The translation mixture was incubated at 30° C for 90 min.

At the end of

the 90 min incubation the translation mix was either analyzed directly or
stored at -70° C.
In order

to

assay

translated proteins,

the

for

GCV kinase

activity associated with

translation mixture was

added to

a

the

solution

containing 100 mM MES (Sigma) pH 6.1 (or in some experiments 100 mM TrisHCl

pH

7.5),

2

mM

magnesium

acetate,

10

mM

ATP,

1

unit

creatine

phosphokinase (Sigma), 6 mM creatine phosphate (Sigma), 1% BSA, and 7.5
µCi 3H-GCV. This reaction was incubated at 30° C for 5-11 h.

At the end

of the incubation period the reaction was extracted with 0.5 M perchloric
acid and centrifuged for 30 min at 4° C.

The supernatant was transferred

to a new tube and recentrifuged for 15 min.
transferred to a new tube and stored at

The supernatant was again

- 70° C for HPLC analysis as

described above.
Cosmid cloning of mutant D6/3/l.

Virion DNA isolated from mutant

D6/3/l was partially digested with BamHI by serial dilution of the enzyme.
The two concentrations of enzyme which produced fragments between 30 and
50 kb in size were selected for the actual cloning steps.

One microgram

of D6/3/l DNA was partially digested with either 4.2 or 2.1 units of
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enzyme.

Cosmid

The products were checked for size on 0.3% agarose gels.

pWE15 (Stratagene) was linearized with BamHI and dephosphorylated with
calf intestinal alkaline phosphatase (Boehringer-Mannheim, Indianapolis,
IN).

The cosmid and partially digested DNA fragments

overnight at 4° C.

were

ligated

The components of the ligation were: 1.5 µl partially

digested HCMV DNA (lµg/µl); lµl linearized pWE (lµg/µl); 2 µl lOX ligation
buffer (0.5 M Tris-HCl pH 7.5, 50 mM MgC1 2 , 50 mM DTT); 2 µl ATP 10 M
The ligation products were packaged into phage with a
packaging kit (Gigapack Gold, Stratagene).

Briefly 4 µl of ligated DNA

was added to a freeze/thaw extract (kit supplied).

Fifteen microliters

of a sonic extract (also kit supplied) was then added.
mixture was incubated at room temperature for 2 h.

This reaction

The packaged phage

were then treated with 20 µl chloroform.
A culture

of~

coli strain NM554 [genotype F-, recA, araD139,

(ara

leu)7696 lacY74, galU-, galK-, hsr-, strA, mcrA(-), mcrB(-)] (supplied by
Stratagene) was grown overnight in Luria broth containing 0.2% maltose and
10 mM MgS0 4 at 30° C.

The bacteria were pelleted for 10 min at 4,000 rpm

in a Sorvall SS34 rotor at 4° C.
MgS0 4 to an OD600 of 0.5.

The bacteria were resuspended in 10 mM

Equal volumes of NM554 cells and packaged phage

solution were incubated at room temperature for 45 min.

In order to allow

expression of beta lactamase, Luria broth (200 µl) was added to each tube
and the tubes were incubated at 37° C for 60 min.
the tubes were gently shaken every 15 min.

During the incubation

The suspension was pelleted

for 1 min at 14,000 rpm in a Beckman microcentrifuge.

The supernatant was

removed, and the bacteria were resuspended in 50 µl of fresh Luria broth.
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The cultures were then plated on Luria agar plates containing 100 µ.g
ampicillin per ml and incubated at 37° C overnight.

Arnpicillin-resistant

colonies were picked to new ampicillin plates.

Each recombinant was

analyzed for cosmid content by the alkaline lysis procedure (98).

Cosmids

containing overlapping regions of the mutant D6/3/l genome were isolated
by

the

large-scale

alkaline

lysis

method

(98)

followed

by

CsCl

purification.
Transfection

of

HFF

with

cosmid

DNA.

Slightly

subconfluent

monolayers of HFF in 6-well tissue culture plates were washed with serumfree Opti-MEM (Gibco).
ml).

Cosmid DNA was diluted in Opti-MEM (6.7 µ.g/0.5

Lipofectin reagent (BRL) (14) was diluted separately in Opti-MEM (17

µ.g/0.5 ml).

Equal portions of cosmid and lipofectin solutions were added

to a new tube and 1 ml of the combined reagents was added dropwise to the
HFF monolayers.
24 h.

The

The cells were incubated with the transfection medium for

transfection medium was

then removed,

infected with HCMV AD169 at an MOI of 1.0.
h,

at which time the

maintenance medium.

and the

cells were

The virus was adsorbed for 2

inoculum was removed and replaced with 3 ml of
After 24 h incubation the medium was removed and

replaced with maintenance medium containing 100 µ.M GCV.
continued for 3-7 days.

Incubation was

Infected monolayers were then scraped from the

plates and passed to uninfected monolayers for further selection in the
presence of 100 µ.M GCV.
Alternatively the monolayers were infected with AD169 2 h before
transfection with cosmid DNA.

At the end of the transfection period

maintenance medium containing 100 µ.M GCV was added directly.

In some
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experiments monolayers were co-transfected with cosmid and AD169 DNA
instead of infection with intact virus.

Selection with GCV was delayed

for 24-48 h post-transfection.
Control monolayers were transfected with cosmid vector pWElS DNA.
The plasmid carries the gene for neomycin resistance for selection.

The

neomycin analogue G418 (400 µg/ml) was added at 48-72 h post-transfection.
In addition there were control monolayers which were mock-transfected to
determine cell viability after Lipofectin exposure.
Two-dimensional gel electrophoresis.

Translation products from in

vitro translation of infected cell mRNA were analyzed by two-dimensional
polyacrylamide gel electrophoresis (113).
isoelectrofocusing (IEF) gel.

The first dimension was an

Tube gels consisting of 8. 8 M urea, 4%

acrylamide, O.S% bisacrylamide, 2% NP-40, 4% ampholine pH S-7 (Pharmacia
LKB), 1% ampholine pH 3-10 (LKB), 0.01% ammonium persulfate and 0.067%
TEMED

(Bio-Rad) were cast in a 20-gel apparatus

Siversprings, MD) and allowed to polymerize for 2 h.
run for 1 h at 200 V.

(Electro-Nucleonics,
The gels were pre-

The anode buffer was 10 mM phosphoric acid and the

cathode buffer was 20 mM NaOH.

A 20 µl volume of the translation reaction

mixture was added to SO µl of sample buffer containing SO mM CHES, 2% SDS,
1% DTT, 10% glycerol.

The samples were run for 16-17 h at 800 V.

The

gels were then extruded into equilibration buffer containing 0.12S M TrisHCl pH 6.8, 2% SDS, 8.6 mM dithiothreitol, 10% glycerol and a trace of
bromphenol blue.
The

first

dimension

gels

were

placed

at

the

top

of

SDS

polyacrylamide slab gels (10% acrylamide, 0.9% bisacrylamide, 0.3% SDS,
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0.05% ammonium persulfate and 10 µl TEMED per 30 ml volume).

The second

dimension gels (SDS-PAGE) were electrophoresed for 2.5-3 h at 30 mA per
gel in a buffer containing 25 mM Tris-HCl pH 8.3, 192 mM glycine.

The

gels were fixed in 30% methanol, 10% acetic acid for 1 hand then enhanced
in 5 volumes of Enlightning (DuPont NEN) for 30 min.

The gels were dried

with heat and vacuum and placed in X-ray cassettes with Kodak XO-MAT AR
film for 48-90 h.
(Kodak).

The films were developed for 4 min in GBX Developer

Development was stopped by rinsing the films in tap water.

The

films were fixed for 2 min in GBX Fixer (Kodak).
Proteins extracted from infected cells were also analyzed by 2-D
gel electrophoresis.

HFF monolayers in 150 cm2 flasks were infected with

stocks of mutant or wild-type strains at an MOI of 1.0-2.0.
were incubated for 48 h in normal maintenance medium.

Monolayers

The medium was then

replaced with methionine-free medium (Gibco) containing 1% FCS, gentamicin
(50 µg/ml),

amphotericin B (2.5 µg/ml)

and 35 s-methionine

(25 µCi/ml,

specific activity 1,000 Ci/rnmol) plus 10% normal maintenance medium.
After 24 h the cells were harvested as follows:

the monolayers were

washed with lX DPBS; the cells were scraped into 4 ml PBS, dispersed by
pipetting and centrifuged at 1,000 x g for 10 min.
in lX DPBS and centrifuged again.
After

the

final

transferred

to

pelleting,
4

microfuge

microcentrifuge for 10 min.
solubilized in 20-30 µl
ampholyte

(9-11

cells

range),

Cells were resuspended

This step was repeated two more times.
were

tubes.

resuspended
The

cells

in 2 ml

were

DPBS

pelleted

and

in

a

The supernate was removed, and the cells were

of urea solubilizer
2%

mercaptoethanol]

[9 M urea,
for

2

h

4% NP-40,
with

2%

frequent
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vortexing.

Solubilized proteins were stored at -70° C until analyzed by

2-dirnensional gel electrophoresis.

The 2-dirnensional gel analysis was

performed by Lori Berg in the laboratory of Dr. Chung Lee at Northwestern
University Medical Center, Chicago, IL.

RESULTS

Selection of HCMV probes.

In order to develop DNA probes for the

rapid detection of HCMV in clinical specimens, regions of the HCMV AD169
genome were selected.

The feasibility of this method was based on the

fact that there is at least 80% homology among the genomes of HCMV strains
which have been tested (26).

The greatest variability has been reported

around the junction of the unique and repeat segments

(90, 147).

The

unique segments are colinear even though restriction endonuclease sites
may be altered (26).

Large restriction fragments from unique regions of

the genome of HCMV AD169,

therefore, would contain sufficient homology

with comparable regions of the genomes of clinical strains of HCMV to
allow hybridization under moderately stringent conditions.
The HCMV AD169 BarnHI B fragment inserted in pBR322 was selected
initially as a probe because of its size (15 kb) and position in the
genome (UL sequence; Figure 2). The intact recombinant plasmid carrying
this fragment was used as the probe in all experiments.
The BarnHI D (13 kb, UL) and H (10 kb, U5 ) fragments cloned in pBR322
were also selected as probes because of size and position in the genome.
The vector sequences were removed from the fragments before they were used
as probes.
In order to determine the minimum amount of homologous HCMV AD169
DNA which each probe could detect, each of the three probes was hybridized
40
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Figure

2.

Restriction enzyme

Greenaway et al . ( 6 7) .

map

of

the

HCMV AD169

genome.

From
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All of the probes

to 100 ng to 10 pg quantities of HCMV AD169 DNA.

detected a minimum of 30 pg of homologous HCMV DNA (Figure 3).
Detection of HCMV DNA in clinical specimens.

A total of 61 urine

specimens submitted for culture to the Virology Laboratory at Children's
Memorial Hospital were processed for direct detection of HCMV with the
biotinylated BamHI B fragment as a probe.
specimen were prepared for
described

in

Materials

Samples of 1 to 3 ml from each

dot-blotting on nitrocellulose

and

Methods.

Similarly

filters

processed

as

samples

containing DNA extracted from laboratory strains of HCMV, HSV-1 and HSV2 were included as controls.
The

comparison of culture

fragment are shown in Table 1.

and hybridization results

for

the

B

Additional information concerning the

length of time required to produce visible CPE and the amount of CPE
present

in

the

culture-positive

specimens

hybridization reactions had been recorded.

was

collected

after

the

There were 15 specimens which

were scored positive by both methods, whereas 14 specimens were scored
positive by culture but negative with the probe.
weakly

positive

with

the

probe

but

remained

Four specimens were

culture

negative.

The

sensitivity of the probe detection method was 52%, and the specificity
was 87.5%.

There was 70.5% agreement between the results of hybridization

and culture methods.

The amount of CPE in cell culture, however, did not

correlate with the probe results.

In several samples the reported CPE was

l+ to 2+, and the probe did not detect the presence of virus.

Conversely,

there were specimens which produced a strong color reaction with the probe
but which yielded only a few lesions in the cell culture tubes.
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Figure 3.
DNA.

Hybridization of selected probes with dot-blotted HCMV AD169
Dilutions of CsCl-purified total genomic

HCMV AD169 DNA were

hybridized with each single-probe BamHI fragment (B,D, and H), as
well as with the combined D and H probes.
shown at the top of each column.
DNA are in column C.

Amounts of

HCMV DNA are

Control solutions containing no

Hybridization was performed for 18 h, and

color development for detection of hybridized probe was allowed for
the maximal 4 h recommended by the manufacturer (BRL).

Probe

1DO

ng

B

•

D

H

D and H

•

10
ng

1 100

ng

pg

31

pg

1

pg

C

TABLE 1. Comparison of results for detection of HCMV in clinical specimens
by cell culture and DNA probe hybridization.
DNA probe
results

Cell culture
Positive
Negative

Sensitivity
(%)

Specificity
(%)

Agreement
(%)

BamHI B
Positive
Negative

15
14

4
28

52

87.5

70.5

BamHI D+H
Positive
Negative

17
4

5
11

81

68.8

75.7

11

5
16

78.6

76.2

77 .1

BamHI H
Positive
Negative

3
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Detection of HCMV with combined BamHI D and H fragment probes.
During the course of these experiments it was reported that a portion of
the HCMV EcoRI restriction fragment I

contains sequences which weakly
The region of the EcoRI

hybridize with mammalian cellular DNA (135).

fragment which is homologous with the cellular DNA is also contained
within the BamHI B fragment.
hybridization,

In order to avoid the possibility of cross-

the HCMV BamHI D and H restriction fragments

(Figure 2)

were used instead of the B fragment in subsequent experiments.
these

fragments

is

in a

region of

homology with mammalian DNA.

the

genome which has

Two changes were made

no

Each of
reported

in the detection

procedure in these experiments, both aimed at increasing the sensitivity
of the detection method.

The first change was the use of two fragments

(BamHI D and H) as combined probes

(151).

The second change was the

elimination of the initial low-speed centrifugation of the urine samples
to prevent the loss of any cell-associated virus present in the specimens.
A total of 37 specimens submitted for culture were processed for
direct detection with the combined biotinylated D and H probes (Table 1).
There were 17 specimens which were positive by both methods, 4 specimens
which were probe negative and culture positive, and 5 specimens which were
weakly positive with the probe but which remained culture negative.
sensitivity of the combined probes was 81.0%,
68.8%.

The

and the specificity was

The agreement between probe and culture results was 75.7%.

The

amount of CPE again did not correlate with the color intensity of the
probe

hybridization.

Of

the

five

probe-positive,

culture-negative

specimens, one was from a patient who had had previous positive cultures.
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Probe hybridization with HSV virion DNA.

There was significant

hybridization of the new probes with HSV controls prepared along with the
clinical samples (Figure 4).

To determine how the observed hybridization

with HSV was related to the use of the new probes, duplicate filters were
prepared with dot blots of HSV-1, HSV-2, and HCMV virion DNA prepared in
the same manner as the clinical specimens.
with one of the fragments.

Each filter was hybridized

Comparison of these two filters shows that the

D fragment hybridized to each of the HSV samples, whereas the H fragment
produced a positive signal only with HCMV DNA (Figure 5).
Analysis of cross-reactivity with HSV-1.
digests of HSV-1 (KOS) DNA were probed with the
fragment.

Southern blots of EcoRI
32 P-labeled

HCMV BarnHI D

Hybridization was observed only with the 4.1 kb HSV-1 EcoRI M

fragment (Figure 6A).

No hybridization was detected between the HSV-1

EcoRI M fragment and HCMV BarnHI fragments other than D (Figure 6B).
Southern blots of restriction digests of the HCMV BarnHI D fragment
were then probed with the

32

P-labeled EcoRI M fragment of HSV-1.

hybridized with the smaller HCMV EcoRI fragment (M),
fragment (Q),

The probe

the largest PstI

the largest XbaI fragments (B,Q), and the largest BglII

fragment (M) (Figure 6C).
Conversely, Southern blots of the HSV-1 M fragment digested with
KpnI

and

BarnHI were

probed with

the

radiolabeled HCMV D fragment.

Hybridization occurred only with the smaller HSV-1 BarnHI fragment and the
larger HSV-1 KpnI fragment (Figure 6D). The region of homology is shown
in Figure 7.

Although the EcoRI M fragment of HSV-1 also contains part

of the coding sequences for the major DNA binding protein (104), the

49

Figure 4.

Dot blot of processed patient urine samples and

HSV and HCMV

controls hybridized with the combined biotinylated HCMV BamHI D and
H probes.

Rows 1 to 3 columns A through E, contain patient samples.

Row 4 contains the control virion samples: A, background; B, HSV-1;
C, HSV-2; D, HCMV AD169; and E, clinical isolate of HCMV.
probe reactivity with the HSV controls.

Note the

A

B

C

D

E

1
2
3

\.11

0
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Figure 5.

Duplicate dot blots of HSV and HCMV controls hybridized with

single HCMV BamHI D or H fragment.

Dot blots

I

(left) were

hybridized with the H probe; dot blots II (right) were hybridized
with the D probe.

Row 1:

HSV-1 virion DNA from cell culture

supernatant: 1-ml (A) and 0.1 ml (B) samples.

Row 2: HSV-1 virion

DNA from cell culture supernatant: 1-ml (A) and 0.1 ml (B) samples.
Row 3: HCMV AD169 virion DNA from cell culture supernatant: 1-ml (A)
and 0.1 ml (B) samples.

Row 4: HCMV AD169 CsCl-purified DNA: 20-ng

(A) and 200 pg (B) samples.

Note the reactivity of the D probe with

HSV samples and corresponding lack of reactivity of the same samples
with the H probe.

I

A

II

A

B

1

1

2

2

3

3

...

B

•

•
Vl

N
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Figure 6.

Southern hybridization analysis showing regions of homology

between restriction

f~agments

in each panel (A through D)
electrophoresed in 0. 7%

of HCMV and HSV-1.

Left-hand lanes

show DNA restriction enzyme digests

agarose

gels

and stained with ethidium

bromide, and right-hand lanes show the corresponding autoradiograms
of the Southern blots made from the same gels and hybridized with
32 P-labeled probes.

Autoradiograms were exposed for 20 h (A and C)

or 48 h (Band D).

(A) Lane 1, EcoRI digest of HSV-1 (KOS) genomic

DNA; lane 2, hybridization with HCMV AD169 BamHI D fragment.
Lane

3,

BamHI

digest

of

HCMV

AD169

genomic

hybridization with pSG17 (HSV-1 EcoRI M insert).

DNA;

lane

(B)
4,

(C) Lanes 5 to 8,

HCMV AD169 D fragment digested with (left to right): EcoRI, Pstl,
Xbal,

and Bglll,

HSV-1

EcoRI

respectively;

M fragment.

lanes 9 to 12, hybridization with

Faint bands

on gel

and autoradiogram

represent partial digestion products. (D) Lanes 13 and 14, HSV-1 M
fragment digested with BamHI and Kpnl, respectively; lanes 15 and
16, hybridization with HCMV AD169 BamHI D fragment.
left of panels C and D are molecular size markers.

Numbers to the

1

(C)

(B)

(A)
2

3

5 6

4

7

8

(D)
13

9 10 11 12

14

15 16

11.3

7.8
6.5
4.5

2.0
1.5

V1
~
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Figure 7.
(59).

Restriction endonuclease maps of HCMV AD169 (67)and HSV-1 KOS
(A)BamHI map of HCMV AD169 showing location of selected probe

fragments B, D, and H.

An expanded map of the D fragment showing

EcoRI, Bglll, Pstl, Xbal sites is shown below. (B) EcoRI restriction
map of Hsv-1 (KOS) showing location of the M fragment. An expanded
map of this fragment is also shown. Enzyme sites are EcoRI (R), Kpnl
(K),

and BamHI

(B).

The shaded area of the expanded HSV-1 M

fragment represents the region of homology with HCMV.

UL, Long

unique sequence; Us, short unique sequence; TRL and TRs, terminal
repeats; IRL and IRS, inverted repeats.
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region of homology between HSV-1 and HCMV includes only sequences from the
DNA polymerase open reading frame (104).
Detection of HCMV with the H fragment probe.
did not cross-react with HSV DNA,

Since the H fragment

it was used alone to see whether a

single fragment would have the same sensitivity as the combined probes.
A total of 35 urine samples were prepared for detection of HCMV in the
same manner as the previous specimens, and the samples were hybridized
with the biotinylated H fragment as the probe.

The results are given in

Table

11 were

1.

Of 14 culture-positive specimens,

probe positive

(sensitivity, 78.6%), whereas 5 specimens were probe positive but culture
negative.

One of the latter samples was from a patient whose previous

specimens had been culture positive.
both methods.

Sixteen specimens were negative by

The specificity for this probe was,

therefore,

76. 2%.

Probe and cell culture agreement was 77.1%.
Although sensitivity and specificity were similar for the combine
(D and H) and single (H) probes, there was a difference in color intensity
of the positive samples.

None of the samples tested with the H fragment

alone showed a color reaction greater than plus/minus.

With the combined

probes, on the other hand, there were several samples which showed 2+ or
greater color reactivity (Figure 4).
Screening of HCMV recombinant library for sequences homologous to
HSV-1 TK.

The homology discovered between the HSV-1 and putative HCMV

DNA polymerase sequences prompted a similar search for homology between
the HSV-1 TK and HCMV.
HCMV recombinant

In order to screen dot blots of DNA isolated from

clones

for homology

to

the

HSV-1

TK gene,

it was
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necessary to

remove

the HSV-1 EcoRI N fragment

(pBR328) of pSG87 (64).

from the vector DNA

The vector sequences would otherwise hybridize

to the pBR322 vector sequences of the HCMV recombinants.

Small-scale DNA

preparations from the 67 recombinant clones of the HCMV AD169 library were
dot- blotted onto nitrocellulose and hybridized with the HSV-1 EcoRI N
fragment labeled with 32 P. After 22 h of hybridization under moderately
stringent

condition,

two

isolates,

numbers

279

and

306,

produced a

stronger signal with the probe than any of the other isolates (Figure 8).
All of the recombinant samples produced a weak signal, which was probably
the result of hybridization between small residual amounts of vector DNA
in the probe preparation and the vector sequences of the HCMV recombinant
plasmids.
DNA isolated from the 67 HCMV recombinants was digested with BamHI,
subjected to agarose gel electrophoresis, and blotted onto GeneScreen Plus
membranes.

The membranes were hybridized with the intact HSV-1 pSG87

plasmid (64) labeled with 32 P.

This meant that both vector (pBR328) and

insert (EcoRI N fragment) were present in the probe.

Figure 9 shows the

results for a representative group of the recombinants including 279 and
306.

The common band in all of the digests represents probe hybridization

with the pBR322 vector of the recombinants.

The other faint bands of

hybridization do not correspond to any insert bands on the original gels
(Figure 9C and 9D).

There are also faint bands in the gel lanes which

occur at the same position as the non-vector bands on the autoradiograms,
but these probably represent undigested or partially digested plasmid DNA
which still contains vector sequences.

The lanes which contain DNA
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Figure 8.

Dot-blot of HCMV strain AD169 BamHI library

for detection of

homology with HSV TK.

Rows

1-6:

inserts.

Plasmid pBR322 with HCMV BamHI
No DNA in positions SL and 6L.

restriction fragment

Positions 6H,I,J, and K,

Hindlll fragments A,B,C,D of VZV DNA inserted into the vector pBR322
(negative controls).

Row 7:

Position 7F, HSV EcoRI N fragment without vector.

7H, pBR322 DNA. Position 7J, 100 ng HCMV AD169 DNA.

Position

The blotted

membrane was hybridized with HSV EcoRI N fragment without vector
sequences.
gene.

Note:

This fragment contains the coding region for the TK

Autoradiogram was exposed for 20 h.

positions

respectively.

3L

and

4G

are

clone

numbers

279

and

306

ABC

DE

FGH

I

JK

L

1

2
3
4
5

6
. 7

O'\

0
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Figure 9:

Southern blots of restriction endonuclease digests of HCMV DNA

cloned fragments to detect homology with HSV TK.

A and C: Southern blot with corresponding agarose gel.

Lanes 1-10:

BamHI restrictions of HCMV fragments inserted in the BamHI site of
pBR322.

Lane 11: pUC18 plasmid DNA.

B and D: Southern blot with corresponding agarose gel.

All lanes

contain BamHI restrictions of HCMV fragments inserted in the BamHI
site of pBR322.

Blots were hybridized with pSG87 (64) which has HSV EcoRI N fragment
insert (HSV TK) in the vector pBR328.

Autoradiograms were exposed

for 20 h.

Note lanes A-10 and B-7 (arrows) contain clone numbers 279 and 306
respectively.
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isolated

from

respectively.

recombinants

279

and

306

(arrows)

are

AlO

and

B7

Unlike the dot-blot preparations there are no insert bands

hybridizing with the intact HSV-1 pSG87 plasmid probe.
BamHI restriction digests of recombinants 8, 215, 279, 306, and 452
were performed to try to resolve the conflicting results between the dotblots and Southern blots of the HGV recombinants.
genomic HCMV DNA

In addition total

was digested with BamHI, HindIII, and XbaI.

Southern

blots of all of these digests were probed with the HSV-1 EcoRI N fragment.
There was no hybridization with any restriction fragments under moderately
stringent

The

conditions.

only visible

hybridization was

to

the

N

fragment control (data not shown).
Since the Southern blots of these selected recombinants failed to
show hybridization with the HSV-1 probe, dot-blots of newly isolated DNA
from the same recombinants was hybridized with the same probe (HSV-1 EcoRI
N

fragment

without

hybridization

with

vector).
recombinants

There
279

was
and

no
306

consistent
as

had been

increase

in

previously

observed on the original dot-blots (Figure lOD, compare with Figure 8).
In fact the pBR322 vector control (Figure lOD column Fl,2) had as strong
a signal as some of the recombinants.
In order to address

the possibility that there was an error in

applying the HCMV recombinant DNA preparations in the original dot-blot
(Figure

8),

the

entire

set of HCMV recombinant plasmids was

isolated and dot-blotted onto nitrocellulose membranes.
were again probed with the HSV-1 EcoRI N fragment.

freshly

These dot-blots

Figures lOA, lOB and

lOC show no marked increase in intensity of probe hybridization for any
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Figure 10.

Repeat dot-blots of HCMV strain AD169 BamHI library to detect

homology with HSV TK (see Figure 8).

The probe for all dot-blots

is the HSV-1 EcoRI N fragment with vector removed.

Exposure was for

24 ,h.

Panel A: Rows 1-5, plasmid DNA from HCMV library samples.

Row 6,

E, pBR322 DNA; F, HSV-1 pSG87 DNA (positive probe control).

Panel B: Rows 1-5, BamHI HCMV library samples. lF, clone 279; 3A,
clone 306 (asterisks). Row 6, same controls as in panel A.

Panel C: Row 1, plasmid DNA samples from HCMV library.

Row 2, A,

last sample from HCMV library; C-F, Hindlll fragments A,B,C,D of
VZV (negative controls).

Row 3, C 100 ng HCMV DNA.

Row 4, E, HSV-

1 pSG87 DNA ; F, pBR322.

Panel D: Repeat isolates of plasmid DNA from clones which originally
hybridized with probe (Figure 8) and random negative clones from
library. Rows 1 and 2: Upper and lower dots in each column are two
different DNA preparations of each recombinant clone.
recombinant plasmids in order: 8, 215, 279, 306,and 452.
pBR322 vector control.
control.

Row 3:

B,

Columns A-E
Column F:

plasmid pSG87 positive probe
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of the

samples

including 279

and 306,

which are both

asterisks on dot blot B (lF and 3A respectively)

labeled with

The variability in

hybridization signal among the recombinants was interpreted to be nonspecific binding of the probe to the DNA samples.
From these experiments it was concluded that although there was
homology between the DNA polymerase coding sequences of HSV-1 and a
specific region of HCMV DNA, there was no evidence that there was homology
between a fragment encoding the HSV-1 TK and HCMV DNA.
HCMV AD169 stock for selection of drug-resistant mutants.

The BamHI

D fragment of HCMV DNA had been found to hybridize with a subfragment of
the HSV-1 EcoRI M fragment (Figures 6 and 7).
data from two published reports

(70, 89)

This evidence plus sequence

indicates,

that the HCMV DNA

polymerase probably is encoded by a 5. 28 kb subfragment of BamHI D.
Further evidence that this region encodes the polymerase would be provided
by mapping mutations which produce resistance to drugs which target the
DNA polymerase.

In order to select for HCMV isolates which have such

mutations, a sample of HCMV strain AD169 was cultured for large-scale
production of a "wild-type" stock.
A three- times plaque -purified frozen sample of HCMV AD169 ( 24/6A/2D,
harvested 4/30/82) was used to inoculate tube monolayers of HFF at an MOI
of 0.01. The supernatant fluid was harvested three days after the cultures
reached 100% CPE.

Virus stock from these tubes was frozen in 10% DMSO

and 10% FCS at -70° C for future use.

All experiments to isolate drug-

resistant mutants started with this "wild-type" stock.
Selection for drug-resistance by plague assay.

Mutants of HSV-1
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resistant to antiviral agents have been selected after a single exposure
to each agent (23,40).

This selection method is most likely to produce

high-level resistance resulting from single mutations.

In order to try

to isolate similar mutants of HCMV the wild-type AD169 stock was titered
in the presence and absence of high concentrations of PAA, Aph and GCV.
The concentration of drug originally used for selection of PAA
mutants, 700 µM (100 µg/ml), was chosen based on a reported method of
selection for HSV-1 mutants (40).

Only a few small plaques were obtained

in all of the wells at this concentration.
were not successful.
(2S-SO µg/ml).

Attempts to pass these plaques

The concentration of drug was lowered to 17S-3SO µM

PAA even at 17S µM (2S µg/ml) produces a more than 20-fold

reduction in titer (Table 2), but a few of the plaques which did appear
in the drug wells were passed to tube monolayers.
yielded viable virus, which was retitered.

Two of these tubes

The percent survival of each

of these plaque isolates (P2SA and PSOA) was no higher than the wild-type.
The second drug which was used to try to select for resistant
mutants was Aph.

The drug concentrations chosen to titer the stock strain

were based on similar experiments with HSV-2 (111) and preliminary testing
of HCMV (6S).

Concentrations from l.S to lS µM produced reductions in

titer ranging from S to 100-fold (Table 2).

Plaques were selected from

wells containing 6 or lS µM and retitered for resistance.
increased resistance was noted even with three-times

Again no

plaque-selected

isolates (see isolates Aph SB/SA/SD and Aph SB/SF/SD in Table 2).
The third drug used for selection of resistance was GCV.

There was

at least a 100-fold reduction in titer of the wild-type in the presence

TABLE 2.

Selection for drug-resistant mutants from direct plaque isolates.

Isolate Number

Drug Selection

Drug Concentration

% Survival**

µM
µM
µM
µM

<<1%
<1%
4.4%
30%

PAA
PAA

140 µM
140 µM

2.S%
2.3%

AD169
AD169
AD169

Aph
Aph
Aph

lS µM
6 µM
l.S µM

<1%
S.S%
22.S%

Aph
Aph
Aph
Aph

Aph
Aph
Aph
Aph

AD169
AD169
AD169
AD169

PAA
PAA
PAA
PAA

P2SA
PSOA

SC
SD
SB/SA/SD
SB/SF/SD

AD169
AD169
AD169
AD169

GCV
GCV
GCV
GCV

700
3SO
17S
87. S

lS
lS
lS
lS

µM
µM
µM
µM

100 µM

so

µM

2S µM
12.S µM

<1%
<1%
<1%*
<1%*
<1%
<1%
<1%
14%

TABLE 2.

(Continued)

D25B
D12B
D12A/50A
D2SB/12A
Dl2B/25A/12B
D12B/25A/12C
Dl2B/25A/12D

GCV
GCV
GCV
GCV
GCV
GCV
GCV

12 .5
12.S
12. 5
12. 5
12. 5
100
100

*Plaque-selected three times.

**

Titer with drug
Titer without drug

x

100

µM
µM
µM
µM
µM

µM
µM

10%
22%
7.6%
21.4%
17.6%*
<1%*
<1%*
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of 25 µM GCV (Table 2).

Individual plaques which did appear at that

concentration were passed to tube monolayers and cultured in the absence
of drug.

Viral progeny from these tubes were retitered in the presence

and absence of GCV.

Percent survival of plaque-selected isolates was

essentially the same as the wild-type AD169 at both low (12.5 µM) and high
(100 µM) concentrations of drug.

For example in Table 2 isolate D25B was

an initial plaque isolate with a 10% survival in 12.5 µM GCV.

Isolates

Dl2B/25A/12C and Dl2B/25A/12C were plaque-selected three times, but the
percent survival at 100 µM GCV was still less than 1%.
Whenever one of these three drugs (GCV, PAA, Aph) was present in
the culture medium at low concentration, the plaques were smaller than
those produced in the absence of drug.

With GCV and PAA the cells within

the plaques were large and usually syncytial.
the

monolayer

surface,

and

initial

foci

Cells remained attached to
of

infection enlarged only

slightly during the course of the assay (14-18 days).

At the higher drug

concentrations no plaques were formed and only rare single enlarged cells
were observed.
Selection for resistant mutants in increasing concentrations of
antiviral agents.

A second method for selection of resistant mutants was

to expose the wild-type stock to increasing concentrations of antiviral
agents.

Individual tube monolayers were inoculated with wild-type HCMV

AD169 virus stock.

The virus was propagated initially in the presence of

low concentrations of each of the three antiviral agents PAA, Aph or GCV.
Each tube monolayer was passed to a new monolayer, whenever there was
close to 100% CPE, or the monolayers were too old to support further viral
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replication.

The time between passages was usually at least two weeks but

often 4-6 weeks.

The progeny of each of the original tubes were always

kept separate, so that any potential mutants would represent individual
mutational events.
The

initial

concentration of

PAA was

140 µM

(20 µg/ml).

monolayers were incubated at this concentration up to 4 weeks.

The

I f the

CPE was less than 100% after this time, the monolayers were passed to new
monolayers, and the same concentration of drug was added to the culture
medium. If 100% CPE was observed before 4 weeks of culture, the monolayers
were passed to new monolayers, and the concentration of PAA was increased
by a 10 µM increment.

Eventually after 8-10 passages, there was close to

100% CPE in three tubes which had been exposed to 700 µM (100 µg/ml) PAA.
When the extracellular virus was retitered at 700 µM PAA, however, the
percent survival was less than 10%.

Although these isolates may be

slightly more resistant to PAA than the wild-type, this does not represent
high-level resistance.

The CPE may have been the result of passage of

virus monolayers at a high MOI, which increases the apparent level of
resistance to antiviral agents (see effect of MOI on GCV mutants measured
by ELISA below) .
Aphidicolin above 7.5 µMis slightly toxic for uninfected HFF. Five
tubes were inoculated with HCMV AD169, and Aph at a concentration of 1.5

µM was added to the cell culture medium.

The same protocol was followed

for passage of monolayers as described above for PAA selection, except
that the levels of increasing drug concentration were 6, 7.5 and 15 µM.
The number of passages at each drug concentration was usually 3 to 4, and
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the total number of passages was 8 to 10.

One of the original 5 tube

lines initiated for selection of resistance to Aph retained evidence of
viral infection at a 15 µM concentration, but there was never 100% CPE,
and only monolayers could be passed for infectivity.
The only drug selection which yielded high-level resistant virus was
GCV.

For GCV selection the frequency of passage of monolayers again

depended on the amount of CPE up to 4 weeks of culture.
selection was at a

drug concentration of 6. 25 µM.

The initial

The levels

for

increasing the concentration of drug were 10, 12.5, 25, 50 and 100 µM.
Virus from three of the original 10 tube lines produced 100% CPE at 25 µM
GCV.

These virus lines were spontaneously able to produce 100% CPE at 50

and 100 µM. High-level resistance, therefore, was achieved after exposure
to 25 µM GCV.
Each of these three GCV-resistant strains of HCMV AD169 was plaquepurified three times.

One plaque-purified sample from each strain was

selected for further characterization.
D6/3/l, Dl/3/4 and Dl0/3/2.

These isolates are designated

All three GCV-resistant mutants produce true

plaques which enlarge during the period of culture in the presence of the
drug.

The plaques are slightly smaller and slightly slower to appear when

the drug is present, but both D6/3/l and Dl/3/4 have extracellular titers
equivalent to the wild-type in the absence of GCV.

Dl0/3/2 appears to

replicate to lower extracellular titer than the wild-type in the absence
of drug, and the plaque morphology differs from both the wild-type and the
other mutants in appearing more syncytial.

The relative reduction in

titer of Dl0/3/2 in the presence of GCV, however, is no greater than that
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of the other two mutants (see below).
Resistance of wild-type and GCV-resistant mutants to other antiviral
£!_gents

measured by

plague

dilution.

Table

3

summarizes

the

cross -

resistance of the three GCV-resistant mutants to other antiviral agents
measured by percent survival.

All three mutants were equally sensitive

to relatively high concentrations of PAA, Aph and ACV.

All three mutants

were slightly more sensitive to AraA compared to the wild-type, but this
hypersensitivity was less than four-fold. GCV is the only antiviral agent
to which the mutants are much more resistant than the wild-type.
One problem in determining percent survival is that the wild-type
does not form plaques in the presence of GCV at higher dilutions of the
stock.

Instead only isolated enlarged cells appear in the monolayer.

The titer of AD169 in the presence of GCV, therefore has been recorded as
the highest dilution in which only rare single infected cells are present.
These individual cells are probably abortively infected, since adjacent
cells never appear to be infected.

Counting these enlarged cells as

plaques means that the calculated titer based on number of plaque forming
units

(pfu)

in the presence of GCV

is probably

too high.

Thus,

an

accurate measurement of percent survival for the wild-type is difficult
to determine by this method.
Resistance
reduction.

of

mutants

and

wild-type

AD169

measured

by

plaque

A second method which was used to determine the relative

resistance of both mutant and wild-type HCMV strains to antiviral agents
was plaque reduction.

To perform the assay a dilution of each virus

strain containing 30 to 50 pfu was inoculated on monolayers in 24-well

TABLE 3.

Percent survival of AD169 and mutants.
Ganciclovir
(100 µM)

AraA
(150 µM)

(700 µM)

Aph
(15 µM)

AD169

<l*

33

<1

<1

6

06/3/1

85

9

<1

<1

12

Dl/3/4

77

10

<1

<1

14

Dl0/3/2

72

4

<1

<1

14

PAA

ACV
(300 µM)

*Values are Titer with drug x 100.
Titer without drug
Titers were determined by plaque dilution assay.
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plates.
drug.

The overlay medium contained serial two-fold dilutions of the
The ID 50 was determined by the micromolar concentration of each

antiviral agent which reduced the number of plaques by 50% relative to
controls without the antiviral agent.
summarized in Table 4.

The results of these assays are

All of the mutants were equally sensitive or

resistant to GCV, PAA, Aph, and ACV.

The mutants appeared again to be

slightly hypersensitive to AraA compared to the wild-type.

The mutant

D6/3/l was no more resistant to PFA than the wild-type but was slightly
hypersensitive to AraT, FIAC

and FIAU.

Since this assay also involves counting plaques, the same apparent
wild-type abortive infection that is observed in plaque dilution assays
is a problem.

Even at the lowest drug concentration of GCV (6.25 µM),

the size of the wild-type plaques was significantly reduced compared to
those produced by the mutants.
Resistance of mutants and wild-type AD169 measured by ELISA.

The

problems encountered with counting wild-type plaques in the presence of
GCV were addressed by using a
resistance.

third method to measure antiviral drug

Both the percent survival and plaque reduction assays may

have overestimated the titer of the wild-type in the presence of GCV.
In order to perform the ELISA,

monolayers in 96-well microtiter

plates are infected with the HCMV strain at an MOI of 0.01.

Replication

is allowed to proceed until the virus control wells show approximately
50%

CPE

(2+).

This

usually takes

4

to

5 days

post- infection.

The

monolayers are then fixed to the bottom of the microtiter plate wells.
Primary murine monoclonal antibody to an HCMV late antigen (see ELISA

TABLE 4.

Plaque reduction assays.
GCV

AD169

S*

AraA

PAA

Aph

ACV

PFA

FIAC

FIAU

AraT

lSO

180

6

lSO

200

4

10

1,000

200

1. s

D6/3/l

lSO

so

180

6

lSO

Dl/3/4

>100

so

180

6

lSO

Dl0/3/2

>100

so

6

7S

s

290

*Values are the micromolar concentrations of each antiviral
agent which reduce the number of plaques by SO% relative to
controls without the antiviral agent.

77
section of Materials and Methods) is added to the fixed infected monolayer
followed after a period of incubation with a secondary antibody, which is
tagged with horse
peroxidase

A substrate

radish peroxidase.

for

horse

is added after another period of incubation and a

product results from enzyme activity on the substrate.

radish
colored

The amount of

color is measured spectrophotometrically and is related to the amount of
viral

Inhibition of viral

antigen produced.

measured

by

a

reduction

in

optical

density

replication by
in

is

the drug concentration producing a

optical density (OD 50 ) of colored product.

is

virus-infected wells

containing GCV in comparison to virus-infected control wells.
endpoint

GCV

50%

The ELISA

reduction in

the

The main purpose of this assay

was to confirm the previously observed sensitivity of the wild-type to
GCV, which was difficult to quantitate by the other two methods described
above.

Only one of the mutants, D6/3/l was tested by this method.

The

endpoints of the wild-type and D6/3/l for GCV were very similar to those
obtained

by

the

plaque

reduction

assay.

The

mutant

was

also

hypersensitive to AraA (Table 5).
The advantage of the ELISA is that production of the viral late
antigen is detected colorimetrically.

This measurement is proportional

to the actual amount of virus replication within each cell, because the
production of late antigen requires viral DNA replication.
measure

the

ability

of an

infectious

particle

to

Plaque assays

produce

infectious progeny, which in turn infect adjacent cells.

additional

In comparison

with plaque assays the ELISA should more accurately reflect the amount of
virus produced by the wild-type within the large single infected cells

TABLE 5.

Resistance to antiviral agents determined by ELISA.
GCV

AD169
06/3/l

3*

125

AraA

PAA

Aph

125

45

2

50

45

2

*Values are the micromolar concentrations which cause
50% reduction of optical density of colored substrate.

-....J

00
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which are observed in the presence of GCV.
It

should be noted,

however,

that

the

actual value

endpoint in the ELISA is dependent on the MOI.

of the

50%

In Figure 11 the effect

of increasing MOI on the OD 50 is demonstrated for both mutant and wildtype.

The OD 50 of the wild-type is approximately 1 µM at an MOI of 0.01

and 20 µMat an MOI of 0.1.
00 50

is

approximately

µM while

80

approximately 190 µM.

At the lower MOI of the mutant D6/3/l the
the

OD 50

at

Even at the highest MOI,

the

higher

however,

MOI

is

the level of

resistance of the mutant is close to 10-fold higher than that of the wildtype.
Analysis
genomic DNA.

of

restriction enzyme

digests

of mutant and wild-type

The assays for cross-resistance of the GCV-resistant mutants

to other antiviral agents did not provide any evidence for a mutation in
the DNA polymerase gene.

In order to investigate the possibility of a

polymerase mutation further, virion DNA was isolated from the wild-type
and the three mutants D6/3/l, Dl/3/4 and Dl0/3/2.

The samples of DNA were

digested with EcoRI,

Southern blots

PstI,

HindIII or Bglll.

of the

digests were hybridized with a plasmid containing the EcoRI M restriction
fragment inserted into the vector pUC18.
with

the

(89,97).

HSV-1

DNA

sequences

which

The EcoRI M fragment hybridizes

encode

the

HSV-1

DNA polymerase

No differences in the positions of the bands hybridizing with

the probe were noted for any of the enzyme digests (Figure 12).

The probe

hybridized with fragments of the predicted size (Figure 2) in all digests.
On some gels on which the restriction enzyme patterns of all three
mutants were compared to that of the wild-type, an extra restriction

80

Figure 11.

Effect of MOI on OD 50 for GCV.

Upper graph, wild- type AD169.

Lower graph, mutant D6/3/1.

Squares, MOI=O.l;

triangles, MOI=0.01.
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Figure 12.

Southern blot with corresponding agarose gel of restriction

endonuclease digests of DNA from mutant Dl0/3/2, Dl/3/4, and D6/3/l
and

~ild-type

AD169 to detect restriction site polymorphism in the

DNA polymerase gene.

Lanes A, F, K, and P: AD169 DNA.
Lanes B, G, L, and Q: Dl0/3/2 DNA.
Lanes c, H, M, and R: Dl/3/4 DNA.
Lanes D, I, N, and S: D6/3/l DNA.
Lanes E, J, 0, and T: EcoRI M fragment of AD169 inserted in pUC18.

Restriction enzymes used for digestion were as follows: Lanes A-E
EcoRI; lanes F-I Pstl; lane J Pstl and Ecol; lanes K-N HindIII; lane
0 Hindlll and EcoRI; lanes P-S Bglll; lane T Bglll and EcoRI.

Probe for Southern blot was HCMV AD169 EcoRI M fragment inserted in
pUC18.

Exposure time of autoradiogram was 24 h.
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fragment of about 2 kb in size was noted in the BglII digests of the
mutants (see lower left gel in Figure 13).

The intensity of the fragment

was less than that of the majority of bands in the digest suggesting that
it might represent a new terminal fragment which is present in less than
1 M concentration.

In order to test this hypothesis Southern blots of

BglII digests (Figure 13) were hybridized with plasmids containing BamHI
restriction fragment J (see Figure 2).

This fragment contains terminal

(isomeric inversion see Figure 1) and junction sequences surrounding the
short unique region of the genome.

The probe hybridized with this new

fragment (Figure 13 autoradiogram) as well as to the large fragments at
the top of the gel.

These large bands are the junction fragments, which

span the repeat regions of both the U5 and UL segments of the genome.
These bands would be expected to hybridize with the probe, because they
contain the common repeat sequences.
There are two other slightly larger fragments which hybridized with
the probe.

These bands may contain some of the repeat sequences in common

with the probe and may represent additional variation in restriction bands
in the repeat region.

This part of the HCMV genome has been shown to be

the most variable among HCMV strains (90,126).
Further investigation of the extra BglII restriction fragment in
the mutants, demonstrated, however, that the fragment is associated with
the source of the viral DNA.

The sample of AD169 DNA which had been

analyzed with the mutant DNAs in Figure 13 (lane 2), was purified from
intracellular DNA.

When a sample of extracellular wild-type virion DNA

was digested with BglII, the extra restriction band was present in the
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Figure 13.

Analysis of Bglll restriction site polymorphism of mutant and

wild-type AD169 DNA.

Southern blot

(upper figure):

lane 1,

intracellular AD169 DNA

digested with BamHI; lane 2, intracellular AD169 DNA digested with
Bglll; lane 3, extracellular D6/3/l DNA digested with BglII; lane
4,

extracellular

Dl0/3/2

DNA

digested

with

extracellular Dl/3/4 DNA digested with BglII;

BglII;
lanes

lane

5

6 and 7,

extracellular AD169 DNA digested with Bglll; lane 8 pSG87 (HSV-1
EcoRI N fragment, vector pBR328) digested with Bglll; lane 9 plasmid
containing HCMV EcoRI D fragment in vector pUC18 digested with
EcoRI.
BamHI

Probe was HCMV AD169 recombinant clone nwnber 279 which has
J

fragment

inserted

into

pBR322.

Exposure

time

for

autoradiogram was 24 h.

Agarose gel

(lower left):

corresponding gel for

Southern blot

above.

Agarose gel (lower right): Lane 1, extracellular AD169 DNA ; lane
2, intracellular AD169 DNA; lane 3, extracellular D6/3/l DNA; lane
4 extracellular Dl/3/4 DNA; lane 5 HSV-1 pSG87 (EcoRI N fragment,
TK); lane 6, lambda DNA.

Lanes 1-4 were digested with Bglll, lane

5 with EcoRI and lane 6 with HindIII.
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wild-type digests as well as the mutants (Figure 13 lower right gel).
There is extracellular AD169 DNA digested with BglII in lanes 6 and 7 of
the lower left gel in figure 13. The concentration of DNA is too low to
vis ualize the extra BglII band, but on close examination of the upper
auto radiogram, faint bands co-migrating with the hybridization bands in
lane s

3 through

5 can be

seen.

Therefore,

this band is

found

in

extracellular DNA in both mutant and wild-type strains and does not
repre sent an altered restriction site that could be associated with GCV
resi stance .
HPLC
Neither

analysis

of drug

cross-resistance

to

anabolism of
other

the

antiviral

GCV-resistant mutants.
agents

nor

restriction

fragment polymorphisms provided any suggestion as to the site of th e
muta tion responsible for GCV resistance .

Biron et al.

( 4)

used ion

exchange HPLC to demonstrate that their GCV - resistant mutant of HCMV AD169
was unable to phosphorylate the drug.
In order to analyze the GCV anabolism by D6/3/l, Dl/3/4 and Dl0/3/2,
a reversed phase HPLC system was deve loped.

Unlabeled GCV and GCV-

monophosphate (a gift from Syntex) were used as standards to determine
retention times and drug stability under the conditions required for
sample preparation.

No standards for the di- and tri-phosphates of GCV

were available, but it was assumed that these compounds would be more
polar than the monophosphate, and therefore , would have shorter retention
times.
On the Partisil ODS-3 column with a mobile phase of 0.02 M KH 2P0 4 ,
GCV-monophosphate had a retention time be tween 4.5 and 5.0 min depending

88
on the flow rate, which was either 1.5 or 2.0 ml/min.

The retention time

for GCV under the same conditions was between 10 and 11 min.
different perchloric acid extraction methods were tested.

Two

When both

standards were exposed to 0.5 M perchloric acid for several hours at room
temperature, the unmodified drug was unstable, but the monophosphate was
unaffected.

When perchloric acid extracts were neutralized with KOH, only

the monophosphate was unstable.

In order to avoid degradation of either

GCV or GCV-monophosphate, infected cell monolayers which had been labeled
with 3H-GCV (Syntex), were washed and resuspended in a small volume of DPBS
and extracted in a 200 µl volume at a final concentration of 0. 5 M
perchloric acid.

The samples were then analyzed immediately by HPLC.

If

necessary, the samples were stored briefly at -70° C.
The analysis of labeled cell extracts was repeated three times, and
the results were the same for each virus strain.

Uninoculated control

cells had low counts in fractions 34-37, which represent unphosphorylated
drug (Figure 14).

The early fractions collected up to five minutes

(Fractions 8-18) have very few counts above background, therefore, there
is very little phosphorylation of GCV by uninfected cells.

The same

analysis of wild-type AD169 infected cells showed very high peaks for both
unphosphorylated GCV (fractions 34-37) and its phosphorylated derivatives
(fractions 8-18) (Figure 15).

By contrast all three mutants have much

lower peaks corresponding to the retention times of the phosphorylated
derivatives (fractions 8-18 in Figures 16 through 18).

From these results

it can be concluded that AD169 phosphorylates GCV as predicted, while the
mutants do not phosphorylate GCV to any great extent.

Since mono-
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Figure 14.

HPLC

analysis of GCV anabolism in uninfected HFF cells.

Fractions were collected at O. 3 min intervals over a Partisil ODS3
reversed phase column.
phase was 0. 02 M KH Po
2

times

of

4

The flow rate was 1.5 ml/min.
.

Fractions 8-18 correspond to the retention

phosphorylated

fractions are 34- 37.

The mobile

derivatives.

Unphosphorylated

drug

HFFCONTROL
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Fi~ure

15.

HPLC analysis of GCV anabolism in AD169-infected cells.

conditions were the same as in Figure 14.
to

retention

times

of

HPLC

Fractions 8-18 correspond

phosphorylated

Unphosphorylated drug fractions are 34-37.

derivatives

of

GCV.

AD169
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Figure 16.
cells.

HPLC analysis of GCV anabolism in mutant D6/3/l-infected
HPLC conditions were the same as in

Figure 14.

Fractions

8-18 correspond to the retention times of phosphorylated derivatives
of GCV. Unphosphorylated drug fractions are 33-38.
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Figure 17.
cells.

HPLC analysis of GCV anabolism in mutant Dl/3/4-infected
HPLC conditions were the same as in Figure 14.

Fractions

8-18 correspond to the retention times of phosphorylated derivatives
of GCV.

Unphosphorylated drug fractions are 33-38.
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Figure 18.
cells.

HPLC analysis of GCV anabolism in mutant Dl0/3/2-infected
HPLC conditions were the same as in Figure 14.

8-17 correspond to
of GCV.

Fractions

retentions times of phosphorylated derivatives

Unphosphorylated drug fractions are 31-35.
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phosphorylation is necessary to activate the drug intracellularly,

the

increased resistance

the

of the mutants

to GCV

can be

attributed to

altered anabolism.
Analysis of GCV anabolism in co-infected cells.

The interaction of

wild-type and mutant D6/3/l in co-infected cells was investigated next.
HFF were co- infected with AD169 and D6/3/l at an MOI of 1. 0 for each
virus.

Control flasks were also infected with either AD169 or the mutant

alone at an MOI of 2. 0.

The cultures were pulsed with 3H-GCV at 72 h post-

infection, and the cells were harvested 24 h later.

The infected cells

were extracted with perchloric acid and the extracts were analyzed by
reversed phase HPLC.
at an MOI of 2.0,

In Figure 19 the wild-type and mutant controls, each

are compared.

The profiles are consistent with the

previous HPLC analysis where drug anabolism by the mutant occurs at a much
lower level than that of the wild-type.

In the upper graph in Figure 20

the wild-type AD169 control at an MOI of 2.0 is compared to co-infected
cells for which the total MOI was 2.0, but the MOI of each individual
virus was 1.0.

Drug anabolism in co-infected cells in this experiment was

approximately 10-fold lower than that of the wild-type.

The experiment

was repeated except that the AD169 control was infected at an MOI of 1.0
instead of 2.0.

The HPLC profiles were similar to those in the previous

experiment, but as might be predicted from the Poisson distribution, the
number of counts in the GCV and GCV-derivative peaks of the wild-type
AD169 control were lower.
cells

would

be

predicted

At an MOI of 2.0 the percent of uninfected
to

be

13. 5%,

while

at

an MOI

of

1. 0

the

percentage of uninfected cells would be expected to increase to 36.8%.

100

Figure 19.

HPLC analysis of AD169 and mutant D6/3/l controls for co-

infection

experiment.

infected at an MOI of 2..

Cell

monolayers

for

each

control

were

HPLC conditions were the same as for the

anabolic studies in Figures 14-18 (phosphorylated derivatives of GCV
in fractions 7-17, unphosphorylated GCV in fractions 32-37).

Cross-hatched bars, AD169 control.
Solid bars, D6/3/l control.
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Figure 20.

HPLC analysis of GCV anabolism in co-infected cells.

graph:

Cell monolayer was co-infected at an MOI of 1.0 for each

virus (total MOI=2).
in

Upper

Figures

14-18

HPLC conditions same as for anabolic studies
except

the

Phosphorylated

derivatives

unphosphorylated

drug

in

flow
of

fractions

infected with AD169 at an MOI of 2.0.

rate

GCV

in

32-37.

was

2.0

fractions
Control

Lower graph:

Solid bars, co-infected cells.

7-17,

monolayer

same as above

except AD169 control monolayer infected at an MOI of 1.0.

Cross-hatched bars, AD169 control.

ml/min.
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nwnber

of

phosphorylation,

and

As

the

uninfected
therefore

phosphorylated derivatives,
however,

still

had more

the

nwnber

twice

of

amount

the

counts

the

counts

as

of

associated with

The GCV derivative

decreases.

than

increases,

cells

the

fractions,

corresponding

fractions in the co-infected cell samples (Figure 20 lower graph).
The wild-type "kinase" would be predicted to be dominant over the
mutant,

if there is no interaction between the enzymes when they are

present in the same cell.

These experiments demonstrate that the mutant

activity does have an effect on the wild-type, because the total level of
GCV phosphorylation in co-infected cells is greatly reduced compared to
the wild-type control.
In vitro translation of mRNA from virus-infected cells.

From the

previous HPLC analysis it is apparent that a viral mutation produces an
alteration

in

the

kinase

activity

which

phosphorylation of GCV in virus-infected cells.

is

responsible

for

the

This suggests that either

the virus encodes the enzyme for this function or that there is a viral
product which modifies a cellular kinase.

Work by Preston (124) with the

HSV TK demonstrated that it is possible to obtain a functional protein by
in vitro translation of RNA isolated from HSV-1-infected cells.

A similar

set of experiments was designed to try to express the GCV kinase function
in vitro.
Tritiated-GCV or 14 C-labeled-GCV was added to translation products
from mRNA isolated from cells 72 h post-infection with either wild-type
AD169 or mutant D6/3/l.

In the initial experiments the pH of the reaction

was 7.5, and the period of incubation for expression of enzyme activity
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was 5 h.

The reason for choosing this pH was that Biron and co-workers

(5) had used pH 7.5 in attempts to express kinase activity from infected
cell extracts.

The products of the in vitro translation reaction were

extracted with perchloric acid and the extracts were analyzed by HPLC.
The conditions for the HPLC analysis were the same as those for the
studies of GCV anabolism (Figures 14-18).

There was no peak corresponding

to phosphorylated derivatives of GCV from wild-type infected cells (Figure
21, upper graph).

The pH of the reaction was changed to 6 .1 for the

second set of experiments, and the incubation was increased to 11 h, but
the results were the same (Figure 21, lower graph).

This lower pH was

used in experiments by Preston (124) for expression of HSV-1 TK activity.
Since GCV is a substrate for the HSV-1 TK, the optimal reaction conditions
of the "GCV kinase" might be similar.
The in vitro translation reactions produced proteins, because the
same mRNA preparations were used in the analysis of infected-cell proteins
by 2-dimensional gel electrophoresis as described below, and consistent
discrete spots were present on all fluorograms of these gels.

The lack

of detectable kinase activity is assumed to be the result of either low
specific activity label or suboptimal conditions for enzyme activity or
both.
Cosmid cloning of D6/3/l DNA.

Marker transfer would be a definitive

method for mapping the enzyme function lacking in the mutants (117).
was

DNA

isolated from extracellular virions of D6/3/l and partial BamHI

restriction fragments were cloned in the cosmid vector pWE15 (Stratagene).
Over 500 ampicillin-resistant colonies were obtained and 120 of these were
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Figure

21.

HPLC

analysis

of GCV anabolism following

incubation with

products of in vitro translation of mRNA.

Upper graph: Analysis of GCV anabolism following incubation with in
vitro translation products of mRNA isolated from uninfected (crosshatched

bars)

and

AD169-infected

(solid

bars)

cells.

HPLC

conditions were the same as for co-infection studies in Figure 20.
The

pH

of

the

expression

reaction was

7. 5

and

the

period of

expression was 5 h.

Lower Graph: Analysis of GCV anabolism following incubation with in
vitro

translation products

of mRNA isolated from mutant D6/3/l

(cross-hatched bars) and AD169-infected (solid bars) cells.

HPLC

conditions were the same as for the co-infection studies in Figure
20.

The pH of the expression reaction was 6.1,

expression was 11 h.

and the time of
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subjected to plasmid DNA analysis.

The DNA from each isolate was digested

with BamHI to determine the size of the fragments present in the cosmid.
In addition the DNA was blotted and probed with AD169 cosmids obtained
from Bernhard Fleckenstein (51) or previously cloned fragments of AD169
DNA

(97).

Cosmid

hybridization pattern.

inserts

were

identified

by

fragment

size

and

Figure 22 shows a group of mutant cosmids, which

were hybridized with two different known AD169 cosmids to identify the
region of the genome represented in the mutant.

The same blot was first

hybridized with cosmid 1075 which spans the HindIII R to L fragments.

The

membrane was stripped and then rehybridized with cosmid 1106, which spans
the HindIII L through D fragments.

The mutant cosmids were derived from

BamHI partial digests of D6/3/l DNA, while the wild-type cosmid probes are
composed of HindIII partial digestion produces.

Note all cosmids have

different hybridization patterns with the two probes except those in lanes
14 and 15.

The cosmid in lane 14 was found on further study to have non-

contiguous

fragments,

and

the

cosmid

in

lane

15

appeared

rearranged vector sequences in addition to HCMV DNA inserts.

to

have

Note there

is no band in lane 15 which migrates with the common vector band (upper
autoradiogram) in all of the other digests.

The hybridization in the

lambda lanes (1 and 17) results from the common cos sequences present in
the pHC79 cosmid vector of the probe.
Eight cosmids were selected for more extensive analysis to see if
the entire genome was represented.

These eight cosmids were chosen,

because they all had different restriction patterns and different patterns
of hybridization with the HCMV AD169 cosmid probes.

It is difficult to
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Figure 22.

Southern blot of restriction endonuclease digestions of cosmid

clones of HCMV mutant D6/3/l DNA.

The same blot was hybridized

first with AD169 cosmid 1075 (ref. 51) (upper autoradiogram).
probe was then stripped,

and the blot was hybridized with AD169

cosmid 1106 (ref. 51) (lower autoradiogram).

Lanes 1and17 of both

autoradiograms, lambda DNA digested with HindIII.

Hybridization of

lambda fragments with the probe results from the lambda
which is part of the cosmid probe construct.
the AD169 cosmid probes is pHC79.
is pWE15 (Stratagene).
restricted

with

BamHI

The

£Q§.

site,

The vector portion of

The vector for the D6/3/l cosmids

Lane 18 of both autoradiograms, pWE15 DNA,
(single

site).

autoradiograms, cosmid D6/3/l DNA restricted

Lanes

3-16

with BamHI.

of

both
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analyze cosmids which span any of the repeat regions, since the wild-type
cosmid probes will hybridize with any fragments containing common repeat
sequences regardless of the attached unique sequences
Since there are four isomeric forms

of the virus,

(see Figure 2).

smaller probes are

required to determine which conformation is present in a given cosmid.
Smaller probes

were

not

available

for

this

region without

extensive

For this reason extra cosmids with different restriction

subcloning.

patterns, which hybridized with repeat regions of the genome were selected
to try to ensure,

that all repeat and junction regions were included.

From the somewhat superficial analysis of these eight cosmids, it would
appear that most, if not all, of the genome is represented.
The

DNA

from

each

of

transfection experiments.

these

cosmids

was

used

for

a

series

Each experiment was set up as follows:

of

1) In

the first experiment cosmid DNA was co-transfected with AD169 purified
virion DNA.

In addition some monolayers were transfected with cosmid DNA

and then infected with wild-type virus.
to the cell culture medium.

After 48 h 20 µM GCV was added

Monolayers were passed to new monolayers in

tubes of flasks and selected with 100 µM GCV.

2) In the second experiment

all monolayers were transfected with cosmid DNA and infected with wildtype virus after 24 h.

GCV

(100 µM)

was

added after another 24 h.

Infected monolayers were passed to new monolayers after 5 to 7 days and
again incubated with 100 µM GCV.

3)

In the third experiment some of the

monolayers were infected first with AD169 and transfected after 2 h.
was added after 22 h.

GCV

The remaining monolayers were transfected first

with cosmid DNA and infected after 22 h with AD169.

After a

2-hour
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adsorption period, GCV (100 µm) was added to the cell culture medium.
Monolayers were passed to tubes and flasks at 5 to 7 day intervals.

The

cell culture medium always contained 100 µM GCV.
The reason for combining infection with transfection is that it is
difficult to transfect the intact AD169 genome because of its large size,
and it is also difficult to obtain large quantities of purified virion
DNA.

The disadvantage of supplying the wild-type DNA in the form of

infectious virus is that there is a high background of wild-type CPE,
which must be titered on new monolayers to test for recombinant virus.
The order of transfection and infection was varied to see if either method
might be more efficient for producing resistant virus.
In all three experiments tubes and flasks were held 4 to 6 weeks
and repeatedly checked for plaque development.

No resistant virus plaques

were detected in any of the three experiments, although single enlarged
cells often persisted after passage to successive new monolayers.
Two-dimensional gel electrophoresis.

Since it was possible to

obtain in vitro translated products from mRNA isolated from virus-infected
cells, these products were analyzed by 2-dimensional gel electrophoresis.
The

proteins

were

labeled

with

35 S-methionine

and

subjected

to

isoelectrofocusing in the first dimension and SDS-PAGE in the second.

It

is possible that there is a point mutation in D6/3/l, which is responsible
for the altered kinase activity.

Isoelectrofocusing would detect a change

in isoelectric point resulting from a single amino acid change or possibly
a small deletion.
or

frameshifts

Point mutations which result in premature stop codons

would be

expected to

produce

lower molecular weight
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A second possibility would be

proteins.

that

the proteins might be
Deletions,

unstable and would not be detected on the gels.

if large

enough, would change the molecular weight of the protein.
Comparison of 2-dimensional gels of mutant and wild-type in vitro
translation products did not reveal any consistent protein change between
the two strains.
all

The majority of proteins were consistently present on
There

fluorograms.

changes

which

dimensional

were

gel

not

were

occasional

reproducible.

electrophoresis

may

quantitative
Technical

contribute

or

qualitative

variations
to

the

in

2-

lack

of

reproducibility.
Comparison by 2-dimensional gel analysis of proteins extracted from
mutant and wild-type-infected cells, however, revealed a protein which was
present in wild-type-infected cells but missing in the mutant-infected
cells.

The arrows in Figure 23 indicate the position of the protein.

The

estimated molecular weight of this protein is 43,000.
Both the wild-type AD169 and mutant D6/3/l stocks were extensively
tested for mycoplasma contamination to eliminate the possiblity, that the
protein could be

of mycoplasmal

origin.

staining, monoclonal antibody specific for
both cells and cell culture fluid.

The

M.

tests

included Hoechst

hyorrhinis, and culture of

All test results were negative.

The experiment was repeated two more times,
difference appeared on the fluorograms.

and the same protein

The protein was not present in

either uninfected HFF cells or in mutant Dl/3/4-infected cells (data not
shown).
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Figure 23.

Fluorograms of 2-dimensional gels of proteins extracted from

AD169-infected cells (A) and D6/3/l-infected cells (B).

Proteins

were labeled 48 h post-infection with 35 S-methionine and harvested
for gel analysis 72 h post-infection.

Arrows indicate position of

43,000 MW protein present in AD169, missing in mutant D6/3/l.
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DISCUSSION

There

were

several

significant

performed for this project.

findings

from

the

experiments

First of all DNA probes were found to be

capable of direct detection of HCMV in clinical specimens.

Coincidentally

one of the probes cross-hybridized with the region of the HSV-1 genome
which encodes the HSV-1 DNA polymerase.

Since the HCMV DNA polymerase had

not yet been mapped, this observation was a significant piece of evidence
for the location of the polymerase on the HCMV genome.
Drug-resistant mutants have been very useful for analyzing the DNA
polymerase locus of HSV.

However, there have been very few HCMV mutants

of any kind reported to date (4,33,34).

Three mutants of HCMV (D6/3/l,

Dl/3/4 and Dl0/3/2), which are resistant to GCV were isolated.

These

mutants were found by HPLC to be deficient in intracellular anabolism of
GCV.

Since GCV must be activated by phosphorylation, the phenotype of the

mutants

suggested

activation.

that

there

is

a

viral

function

required

for

this

No HCMV virus encoded TK has yet been found, although GCV is

a substrate for the HSV-1 TK.
Detection of a protein in wild-type infected cells, which is absent
in D6/3/lfinding

of

and Dl/3/4-infected cells is probably the most significant
this

demonstrated for

investigation.
this protein,

No
but

kinase

the MW

activity

(43,000)

has

and the

yet

been

temporal

appearance (early post-infection) are similar to those of the HSV-1 TK.
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Development of DNA probes. The biotinylated probes developed for
this project were each able to detect HCMV in clinical specimens, provided
that enough viral DNA was available to be detected by probe hybridization.
Control experiments (Figure 3) indicated that the limit of detection was
around 30 pg for totally homologous DNA. The studies using the HCMV BamHI
B probe detected cell-free virus, since the low-speed centrifugation step
of the protocol would have removed any virus associated with intact host
cells.

The sensitivity of the test with this probe was low for two

possible reasons.
was

high.

(2)

(1) The nonspecific color background of the membrane
There

may

have

been

a

significant

proportion

of

intracellular virus which was removed by the low-speed centrifugation.
Color background is

a

technical problem and was

corrected in later

experiments by maintaining a constant flow of the streptavidin solution
over the nitrocellulose membranes.

The low-speed centrifugation step was

eliminated to preserve intact cells.

This meant, however, that mammalian

cellular DNA could be present in the dot blot preparations.
During the time that the B fragment probe was being tested, there
was a report (135) that DNA sequences within this fragment could hybridize
weakly with cellular DNA sequences.

In other studies (18,151) two probes

from different regions of the genome were used.
possibility

of

cellular

DNA

hybridization

and

In order to avoid any
to

investigate

the

possibility that a combination of two probes would raise the sensitivity
of the procedure, both BamHI D and H fragments were chosen for further
development as probes (Figure 2).

With these new probes the sensitivity

of the test procedure increased from 52 to 81%, but the specificity
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declined from 87. 5 to 68. 8%.

The decreased specificity could be the

result of nonspecific binding of the biotinylated probe to substances in
the urine samples.
speed

Microscopic analysis of materials pelleted by low-

centrifugation

showed

that

some

urine

specimens

contained

a

significant number of cells, crystals, or bacteria.
There was unexpected cross-reactivity between the HCMV D fragment
and HSV DNA controls, which will be discussed below.
H fragment was tested as a single probe.

For this reason the

The sensitivity and specificity

results were similar to those of the combined D and H probes, but it was
noted

that

the

This suggests

reaction.
sensitive

positive

than

the

specimens
that a

combined

produced

only

a

plus/minus

single probe might prove

probes.

One

reason

for

the

color

to be less
decreased

sensitivity would be that there is only one region of each genome which
can hybridize with the probe, therefore the total probe signal per genome
would be reduced.

In addition there is the possibility of variation in

DNA sequence among clinical strains of HCMV, which might decrease the
homology between the probe and the corresponding region of the clinical
strain to be detected.
Homology between HSV-1 and HCMV.

The cross-reactivity between the

HCMV BamHI D fragment and the HSV controls was investigated further.
HSV EcoRI M fragment specifically hybridized to this fragment.

The

The total

genomic homology between HSV-1 and HCMV was originally reported to be only
5% (79).
specific

HSV-1 and Epstein-Barr virus show homology which is confined to
sequences

(29,60,121).

coding

for

proteins

having

related

functions

Similar limited homology has now been shown to exist between
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HSV-1 and HCMV (89,97).
The HSV-1 M fragment codes for part of the viral DNA polymerase
(21,59).

Cross hybridization with the HCMV BamHI D fragment was observed

within a region containing approximately 2.8 kb of the coding sequences
of the HSV DNA polymerase (Figure 7).

It has been confirmed by others

that the specific hybridization between HCMV and HSV-1 observed in this
study represents homology of that portion of the two polymerases which is
highly conserved functionally among herpesviruses (58,89).
Similar hybridization experiments were also performed to determine
if there is homology between the HSV-1 TK and any portion of the HCMV
genome.
with

No separate viral TK activity has been reported to be associated

HCMV

infection

(49,177),

and

there

have

been

no

reports

of

experiments performed to determine possible homology between the HSV-1 TK
gene and HCMV DNA.

The fact that ACV is not phosphorylated in HCMV-

infected cells has been interpreted as further evidence that HCMV does not
encode

a

TK

(5).

HCMV

is

sensitive

to

GCV,

however,

and GCV

is

phosphorylated by the HSV-1 TK.
When the first dot-blot which was made from the HCMV BamHI library
was probed with the HSV-1 TK sequences,

there were two samples which

hybridized more strongly with the probe (Figure 8).

Attempts to reproduce

these results by probing restriction endonuclease digests of the BamHI
library (Figure 9) or repeat dot-blots (Figure 10) were unsuccessful.

The

two recombinants which hybridized with the HSV-1 TK region on the original
dot-blots contained the BamHI G and J fragments.

These fragments contain

sequences from the short repeat, which has a high G+C content (129).

The
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high G+C content could cause non-specific probe hybridization, which might
explain why the original results were not reproducible.

It should also

be noted that the 67 BamHI recombinant clones tested for HSV-1 TK homology
may not constitute a complete HCMV library, since not all HCMV fragment
inserts have been identified.

The conclusion from these experiments and

those of others (49,177) is,

that there is not a gene encoded by HCMV,

which is homologous at the DNA level to the HSV-1 TK.
GCV-resistant mutants.

The fact remains, however, that GCV is an

effective therapeutic agent

for treatment of HCMV infections and GCV

requires

intracellular

Resistance

to

GCV

phosphorylation

for

theoretically could be

its

antiviral

activity.

caused by mutations

different genes of HCMV, the polymerase or the "GCV kinase".

in

two

Biron and

co-workers(4) demonstrated that a GCV-resistant mutant of HCMV AD169 was
deficient in kinase activity.
Dl/3/4

and

Dl0/3/2,

which

The three GCV-resistant mutants D6/3/l,

were

isolated

during

this

project,

were

similarly characterized to determine what function was altered.
Multiple restriction digests of all three mutants were probed with
the wild-type EcoRI M fragment, which encodes the polymerase gene (Figure
12).

The purpose of this experiment was to determine if a restriction

site might fortuitously have been gained or lost in the polymerase gene
at the site of the mutation.

No differences in the hybridization patterns

could be detected.
In

BglII digests of the mutant DNAs, however, there was an extra

band which was present in less than one molar concentration.

Quarter or

half molar concentrations are typical of terminal and junction fragments
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For this reason the Bglll digests were probed with a

of HCMV (90).

plasmid containing the BamHI J fragment of AD169.

There was hybridization

with the extra Bglll fragment as well as two other faint fragments (Figure
13 lower gel).

These other fragments may represent terminal variability,

which has been described for this region (172).

On further investigation,

however, it was demonstrated that although the extra fragment was absent
in digests of AD169 DNA extracted from infected cells, it was present in
extracellular virion DNA of AD169 (Figure 13).

HCMV DNA is replicated

intracellularly as concatamers, therefore, the new terminal fragments may
be generated when the DNA is packaged into virions.
Restriction enzyme analysis did not yield any evidence of altered
restriction sites either in the region of the HSV polymerase gene homology
or in digests of the total genome.

This does not, however, rule out a

mutation in the polymerase gene, since there are many sites where a base
change

would not

affect

a

restriction

enzyme

recognition

sequence.

Similarly changes in any other region of the genome would not necessarily
produce detectable restriction polymorphisms, especially since only five
restriction endonucleases were tested.

Another approach to determining

whether the GCV resistance of the mutants was a result of changes in
polymerase or kinase function was to develop a drug-resistance profile for
each mutant.

HSV-1 drug-resistant mutants were found to cluster in two

genes, the TK and the polymerase depending on the target of the individual
drug.

There was often cross-resistance among drugs affecting the same

gene.

For example PAA-resistant mutants were also resistant to PFA and

AraA (20,21,22).

Cross-resistance of the GCV-resistant HCMV mutants was
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tested first by plaque dilution to determine percent survival (Table 3).
Relatively high concentrations of each antiviral agent were chosen.

The

mutants were similar to the wild-type in their sensitivity to PAA and Aph.
Both mutants and wild-type were relatively resistant to ACV.
GCV-resistance
appeared

to

of

be

the

mutants

was

confirmed.

slightly hypersensitive

to

The

mutants,
This

AraA.

High-level
however,

was

somewhat

surprising, since AraA is thought to be phosphorylated by cellular kinases
(93).

There are two problems with this method of quantitation.
all only one concentration of drug is tested.

First of

It is conceivable,

that

lower concentrations might indicate more subtle differences in sensitivity
or resistance between mutants and wild-type.

The second problem is that

the wild-type does not form plaques in the presence of GCV.

At higher

dilutions of the stock (above 1 x 10- 3 , MOI=0.01) only enlarged single
cells

appear.

These

cells

probably

represent

abortive

infection,

therefore, the amount of infectious virus produced, if any, is much lower
than that of plaques produced in the absence of drug.

The determination

of the titer in the presence of GCV, which is measured by the highest
dilution with only single cells, is, therefore, overestimated.
Plaque reduction assays for quantitation of drug resistance are
performed at

a

single

dilution of virus.

This

dilution

is

usually

selected such that 30-50 pfu are inoculated onto a monolayer in a 24-well
plate.
MOI.

Inoculation of this amount of virus represents a relatively low
A range

of drug

concentrations

can,

therefore,

be

tested

for

inhibition of plaque formation at a single MOI. This avoids one of the
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problems with the plaque dilution method.

The results of the plaque

reduction assays confirmed the pattern of sensitivity of mutants and wildtype determined by plaque dilution.
the mutants,

and the

resistance

No differences were detected among

to GCV and hypersensitivity to AraA

relative to the wild-type were reproducible.
tested for susceptibility to AraT,

Mutant D6/3/l was further

FIAC and FIAU by plaque reduction

assay.

This mutant was found to be slightly hypersensitive to all three

drugs.

This is somewhat unexpected, because although AraA is probably

phosphorylated by the cellular TK (93), AraT, FIAC and FIAU at least in
HSV-infected cells are phosphorylated by the viral TK.
The plaque reduction assays still have a problem similar to one
associated with plaque dilution, namely the fact that the wild-type virus
does

not

form plaques

in the

presence

of GCV.

In order

to better

quantitate the sensitivity of the wild-type virus to this agent an ELISA
was developed.
The

ELISA detects a late HCMV antigen which requires viral DNA

replication for its production (142).

Since GCV inhibits DNA replication,

synthesis of this antigen is especially sensitive to the effects of the
drug.

The measurement of the reduction in optical density with increasing

concentrations of GCV is proportional to the amount of virus produced in
each infected monolayer.

This is a much better method for determining

actual virus replication beyond abortive infection.
ELISA

confirmed

the

level

of

sensitivity

of

the

The results of the
wild-type

previously determined by plaque dilution and plaque reduction.

to

GCV

The high-

level resistance to GCV and slight hypersensitivity to AraA of D6/3/l were

124
also confirmed.
There was no evidence for cross-resistance of the mutants to any of
the drugs dependent only on polymerase activity (PAA, PFA, or Aph), but
there still could be a mutation in the polymerase gene which did not
affect the interaction of the enzyme with these three antiviral agents.
In order to determine whether these mutants were

phenotypically

similar to the one described by Biron et al. (4), HPLC analysis of GCV
anabolism within cells infected with either mutants or wild-type AD169 was
performed.

A reversed phase system was developed to distinguish GCV from

its phosphorylated derivatives.

This was different from the ion exchange

HPLC method of Biron and co-workers (4), but the results were highly
reproducible.

All three mutants were remarkably deficient in the ability

to phosphorylate GCV.

The lack of activation of GCV within mutant-

infected cells could account for the increased resistance, but there could
be another mutation contributing to the high-level resistance, which is
phenotypically masked by the lack of kinase activity.
GCV anabolism was also studied in co-infected cells.

I t might be

expected that the wild-type enzyme would be dominant over the mutant,
therefore, in co-infected cells the wild-type enzyme would be functional
and GCV would be phosphorylated.

The amount of phosphorylation of GCV in

co-infected cells was approximately 10% of that of wild-type- infected
cells at the same MOI.

These results suggest that the mutant enzyme

competes for the GCV substrate, or that the enzyme is a multimer.

In the

latter case mutant subunits mixed with wild- type could cause loss of
function for the complete multimer.

The mechanism of the interaction of
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wild-type and mutant enzyme activities, however, cannot be determined from
these experiments.
An experiment which would be helpful in studying enzyme activity in
co-infected cells, would be to vary the relative amounts of each virus for
co-infection at the same total MOI.

Such an experiment was attempted, but

the only radiolabeled-GCV which was available was the
Burroughs-Wellcome.

14

C-GCV received from

The specific activity of this labeled drug was 500

mCi/mmol) while the specific activity of the 3H-GCV from Syntex was three
times higher.
cells

from

The number of counts of the GCV taken up by the infected

the medium was

not high enough to produce

significantly

increased peaks of phosphorylated derivatives from even wild-type-infected
cells.

One other problem with this label is that the

portion of the molecule (Figure 24A).

14 c

is in the guanine

The bond between guanine and the

acyclic ring is somewhat labile, therefore when it is broken,
guanine remains, which can be phosphorylated by cellular kinases.

labeled
These

kinases are present in both mutant and wild-type-infected cells, and the
reversed phase HPLC system cannot distinguish the phosphorylation products
of GCV and guanine.
control

and

There were similar peaks of less than 100 cpm in

co-infected cells

performed with

14 C-GCV.

when

the

co-infection experiment

was

From Figure 24B it is apparent that the lability

of the bond between guanine and the acyclic ring is not a problem with the
3H-GCV,

because the label is in the acyclic ring.

the remaining guanine is not labeled.

If the bond is broken

The labeled acyclic ring apparently

does not co-migrate with any GCV anabolic products, because mutant and
wild-type HPLC profiles are dramatically different.

Unfortunately the
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Figure 24.

The structure of GCV from different sources with the position

of the label indicated (asterisk).
label on CS.
ring.

(B)

3H-GCV

(A) 14 C-GCV (Burroughs-Wellcome);

(Syntex); label on two hydrogens of acyclic
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only source of radiolabeled GCV is as a gift of the pharmaceutical
companies which developed the drug,

and the higher-specific activity

tritiated compound is no longer available.
Strategies for mapping the GCV kinase activity.

The HPLC analysis

of the mutants, however, did at least show that a kinase activity, whether
virally encoded or virally modified, was greatly reduced.
approaches were taken to try to map the mutation:

Three different

1) in vitro translation

and expression of kinase activity; 2) transfer of resistance from a mutant
cosmid library to wild-type AD169; 3) 2-dimensional gel electrophoresis
analysis of mutant and wild-type infected cell proteins.
The experimental design for the in vitro translation approach to
mapping

the

kinase

function was

based

on the

HSV-1

TK

experiments

performed by Preston (124) in which in vitro translated infected cell RNA
produced an active TK product.

In addition some experiments were based

on methods used by Biron and co-workers (5) to try to express HCMV "GCV
kinase" activity from cytosolic extracts of wild-type infected cells.
If wild-type-infected cell mRNA could be translated and expressed
in vitro, individual cosmid clones of the HCMV genome could be used to
arrest the translation and expression of the enzyme activity.

In this

manner the translation product could be mapped to a specific cosmid.

More

specific mapping within the cosmid region could be achieved by the same
type of experiment using subclones of the cosmid to arrest translation.
The optimal conditions for the activity of the HCMV enzyme are
entirely unknown,

therefore,

in order to try to develop an in vitro

expression system similar to that of the HSV-1 TK, two different sets of
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experimental conditions were used (Figure 21).

For the first set of

experiments the pH was 7.5 and the period of time allowed for expression
was 5 hours.

The pH was later changed to 6.1 and the expression time was

either 5 hours or 11 hours.

There were never any measurable peaks of

phosphorylated GCV anabolic products after HPLC analysis of the expression
reactions.
the

The most likely explanations for the negative results are

optimal

reaction

conditions

for

the

kinase

activity

1)

differ

significantly from those of the HSV-1 TK, and therefore, were not met by
the in vitro expression system; 2) the mRNA which was isolated at 72 h
post-infection did not represent the peak of temporal transcription of
kinase message,

therefore there was insufficient message present for

translation of the kinase product; 3) the specific activity of the labeled
GCV substrate was not high enough to detect the phosphorylated products.
Any combination of these explanations could also be responsible for the
negative findings.

In support of the last possibility, it was shown that

the expression of the HSV-1 TK required labeled substrate of very high
specific activity (124).

The highest specific activity of labeled GCV

that was available was approximately 30-fold lower than that of the HSV1 TK substrate.
Another approach to mapping the kinase function was transfer of the
resistance

from mutant

to wild-type virus

regions of the mutant genome.
made.

The

wild-type

by

specific cosmid-cloned

A cosmid library of the mutant D6/3/l was

genome

was

represented

extracellular virion DNA or infectious virus.

by

either

purified

The large size of the HCMV

DNA genome makes it difficult to transfect intact.

An additional problem
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with transfection of the DNA is that HFF take up exogenous DNA much less
readily than do many cell lines, and unfortunately there is no cell line
which is permissive for HCMV replication.
transfecting

HFF with

a

marker

plasmid

Three different methods of
(cosmid

pWE15

which

encodes

neomycin resistance) were tested: 1) calcium phosphate precipitation; 2)
electroporation; and 3) liposome-mediated transfer with Lipofectin (BRL).
Transfection was measured by resistance of cells to the neomycin analogue
G418.

The only method which was successful was the third method.
In order to try to transfer resistance from mutant to wild-type

virus different combinations of transfection order and form of the wildtype genome were used.

In some experiments both mutant cosmid and wild-

type naked DNA were co-transfected.

In other experiments the wild-type

genome was in the form of infectious virus.

HFF were either infected

first and then transfected with individual mutant cosmids

(46)

or the

order of transfection and infection was reversed (157).

No recombinant

virus

The

was

isolated

from

any

of

these

experiments.

technical

difficulty of transfection of DNA into fibroblasts may have been the major
reason for the lack of detectable recombination.

It is also possible that

the high-level resistance of the mutant to GCV is the result of more than
one mutation.

If this is the case, marker transfer of the GCV resistance

with a single cosmid may not be possible.
The third approach which was taken to map the kinase activity was
analysis of viral proteins by 2-dimensional gel electrophoresis.

The

initial strategy was to compare in vitro translation products from mRNA
isolated from mutant D6/3/l

and wild-type AD169.

If differences

in
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protein products

could be detected,

it might be possible

translation of particular proteins with cosmid DNA.

to arrest

The disappearance of

specific proteins from the 2-dimensional gels could serve to map those
proteins to a 30 to 40 kb region of the genome.
No reproducible differences in in vitro translated protein products
of the mutant and wild-type were observed.
isolated at 72 h post-infection,

It is possible that the mRNA

which was used for the translation

reaction,

did not contain sufficient message to produce a detectable

protein.

The reason that the mRNA was isolated at 72 h post-infection was

that the HPLC analysis of GCV anabolism indicated that the enzyme activity
was present between 72 and 96 h post-infection.

It could be that the

protein is stable, but the message is not, therefore mRNA isolated at 2448 h post-infection might represent the peak of kinase mRNA production.
Proteins extracted from cells infected with virus were also analyzed
by 2-dimensional gel electrophoresis.

A reproducible protein difference

between the two extracts was found by this analysis.

A protein is present

in wild-type-infected cells and missing in mutant D6/3/l-infected cells
(Figure 23).

It is also missing in Dl/3/4-infected cells and uninfected

cell controls (data not shown). Interestingly the approximate molecular
weight of the protein appears to be 43,000, which is very close in size
to that of the monomers of HSV-1 TK (136).
protein

may

be

an

induced

or

modified

It is possible that the

cellular

protein,

similarity to the size of the HSV-1 TK is purely coincidental.

and

that

The fact

that the protein is not present in either uninfected or mutant-infected
cells, however, strongly suggests that it is associated with GCV kinase
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activity.

Further evidence of the specific function of the protein will

be required to confirm this association.
Since the most promising experimental results were obtained with the
2-dimensional gel analysis of infected cell proteins, a logical next step
would be to extract the protein from the gel and to try to determine a
partial amino acid sequence.

The amino acid sequence could then be used

to map the coding region on the HCMV genome.

If the coding sequence of

the protein is found to be part of the viral genome, there are several
possible approaches to determine its function and its role, if any, in GCV
anabolism.
The wild- type

gene

could be used as

corresponding mutant DNA sequences.

a

probe

to

identify the

The availability of both mutant and

wild-type genes would permit DNA sequencing, which could determine if
there is indeed a difference in this region of the genomes of the two
virus strains.

Finding a change at the DNA level, however, still does not

link this region with GCV kinase function.
The gene from the mutant, however, could be used for marker transfer
studies to see if recombinant virus resistant to GCV can be detected.
This may not work, however,

if more than one mutation is required for

high-level GCV resistance.
A more direct approach to determine function would be to clone the
gene or cDNA in an expression vector.

Selection of the best vector and

cell system would require some preliminary testing.

It might then be

possible to detect kinase activity in cell lines which are much easier to
work with than HFF.
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HCMV is the only member of the human herpesviruses for which no TK
gene has been found.

The GCV kinase activity defined by these mutants is

the closest HCMV viral function to that of the HSV-1 TK, which has been
characterized to date.
for

HCMV

available

at

Since GCV is the most effective antiviral agent
the

present

time,

it

will

be

important

to

characterize the kinase activity which is responsible for HCMV resistance.
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